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ABSTRACT 
microRNA mediated regulation of APP gene expression 
Neha Patel  
Aleister J. Saunders PhD 
 
 
Production of the Aβ peptide by the regulated intra-membrane proteolysis of the β-
amyloid precursor protein (APP) by the, α, β and γ secretase enzymes is the central 
biological pathway in Alzheimer’s disease (AD). A number of studies have shown that 
APP over-expression, resulting from either a genomic locus duplication or alteration in 
the APP regulatory sequences, can lead to development of early-onset Alzheimer’s 
disease (AD). Therefore, understanding the regulation of APP expression could provide 
valuable insight in to the genetic basis of the disease and illuminate novel therapeutic 
avenues for AD. Here we test the hypothesis that APP protein levels can be regulated by 
miRNAs, evolutionarily conserved small non-coding RNA molecules that play an 
important role in regulating gene expression. Utilizing human cell lines, we demonstrate 
that brain expressed miRNAs predicted to target APP 3’UTR bind to their putative target 
sequences in the APP 3’UTR and negatively regulate reporter gene expression. Over-
expression of these miRNAs, but not control miRNAs, results in translational repression 
of APP mRNA and significantly reduces APP protein levels. For all miRNA over-
expressed, except one, APP mRNA levels are not altered suggesting that these miRNAs 
result in translational inhibition while one miRNA does result in decreased APP mRNA 
levels. We also demonstrate novel expression of microRNA in the brain. We show that 
mir-324-5p and miR-17-5p are expressed in neurons and microglial of the hippocampus 
of the human brain and miR-324-5p is also shows microglial expression in the brain 
 xiii
white matter. Disruption of miRNA mediated expression regulation might lead to 
increased APP levels and increased disease risk. To test this hypothesis, we determined 
genetic variations within the APP 3’UTR of probands from early onset familial 
Alzheimer’s disease families linked to the APP-region on chromosome 21. We identified 
a rare sequence variant predicted to be located in a putative miRNA target site. Our 
functional data suggests that the minor allele of this variant disrupts miRNA binding to 
its target, resulting in potential dysregulation of APP mRNA and protein expression in 
vitro. Our results demonstrate that human APP levels can be regulated by miRNAs in 
vitro, and that rare genetic variants within the 3’UTR of APP may alter miRNA mediated 
regulation of APP mRNA, thereby increasing APP levels and possibly increasing AD 
risk. 
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CHAPTER 1: INTRODUCTION 
 
BACKGROUND AND SIGNIFICANCE: 
        Alzheimer’s disease (AD) is a neurodegenerative disorder which is the most 
common form of dementia. This disease causes memory loss and problems with 
cognition and behavior. The elderly are particularly susceptible to AD. It is one of the 
greatest public health concerns in the United States. Alzheimer’s is a progressive 
brain disorder that gets worse over time , and is fatal making it the fifth leading cause 
of death in those aged 65 years and above (Plassman, Langa et al. 2007). The 
frequency of AD has increased over the last  40 years since people are living long 
enough to develop the disease, making age the biggest risk factor for AD (Evans, 
Smith et al. 1991). Currently 5.3 million people in the United States have 
AD(www.alz.org). Taking into consideration the increase in life expectancy this 
number is predicted to quadruple by the year 2050 (Yaari and Corey-Bloom 2007). 
To date there is no cure for Alzheimer’s disease. Current standard treatments or 
therapies available treat only the symptoms of the disease but do not target the 
underlying pathological cause of the disease. Therefore it is important to understand 
the genetic and molecular mechanisms leading to the development of AD in order to 
not only get a better understanding into the biology of the disease but also to develop 
potential novel therapeutics. 
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GENETICS OF ALZHEIMER’S DISEASE: 
         There are two main forms of AD: early onset and late onset. Since age is by far 
the most important risk factor for the disease, approximately 90% of AD cases are 
late onset AD (LOAD), where people develop Alzheimer’s after 65 years of age. The 
ε4 allele of apolipoprotein E (Apo E) is the major genetic risk factor for LOAD 
(Strittmatter, Saunders et al. 1993). Three alleles are expressed at the apoE locus: ε2, 
ε3 and ε4. ε3 allele is the most common allele in the general population with an allele 
frequency of 78%. The ε4 allele has a frequency of 14% in the normal population 
whereas in LOAD patients the frequency is observed to be 40% (Strittmatter, 
Saunders et al. 1993). The ε4 allele confers increased risk for LOAD, by decreasing 
the age of onset, in a dose dependent manner therefore making it the greatest risk 
factor LOAD (Corder, Saunders et al. 1993).  
       Early Onset Alzheimer’s Disease is a rare, autosomal dominant form of the 
disease that develops in individuals before 60 years of age. Mutations in three genes 
are associated with EOAD: APP gene on chromosome 21, PS1 (Presenilin 1) on 
chromosome 14 and PS2 (Presenilin 2) on chromosome 1. (Mullan, Crawford et al. 
1992; Schellenberg, Bird et al. 1992; Levy-Lahad, Wijsman et al. 1995).  All the 
mutations in these genes account for 5% of all AD cases and affect APP processing 
and Aβ production. Missense mutations in APP gene were the first genetic cause of 
EOAD to be indentified. These mutations in APP lead to approximately six to eight 
times more Aβ production and  formation of more dense aggregates (Tanzi and 
Bertram 2005). Studies have identified PS1 missense mutations to cause the most 
aggressive form of AD leading to onset of symptoms before 50 yrs of age (reviewed 
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in (Hardy 1997)). Therefore missense mutations in either APP or PS-1 and PS-2 
genes lead to the production of a more toxic form of Aβ. All the Presenilin mutations 
result in one major biochemical alteration which is a relative increase in the ratio of 
Aβ42 to Aβ40 peptide (Scheuner, Eckman et al. 1996). 
      Another genetic risk factor for development of AD is overproduction of APP due 
to increased APP gene expression. This situation occurs in Downs syndrome 
patients(Podlisny, Lee et al. 1987). An extra copy of chromosome 21 in Down’s 
syndrome patient’s results in APP over expression and increased Aβ production 
therefore leading to AD symptoms early in life, 50 years earlier than the age of onset 
of AD compared to the normal population (Rumble, Retallack et al. 1989; Findeis 
2007). It has also been reported that APP gene locus duplications on chromosome 21 
is believed to cause AD pathology. Similarly to Down’s Syndrome pathology this 
extra copy of the APP gene is a major cause of the large AD incidence in these 
patients (Podlisny, Lee et al. 1987; Rovelet-Lecrux, Hannequin et al. 2006). 
Therefore an increased expression of the APP gene itself can cause an increase in the 
production of Aβ42 and subsequent Aβ deposition thereby increasing AD risk. Thus 
understanding the mechanism of APP gene regulation is important for our 
understanding of AD pathogenesis. Therefore in our study, we extended this 
investigation to identify novel regulators of APP gene expression 
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AD PATHOLOGY: 
         Neurodegeneration in AD is characterized by two major pathological features 
which include neuritic amyloid plaques and neurofibrillary tangles which affect 
neurons in the brain particularly in the hippocampus and cerebral cortex.  The neuritic 
plaques are composed of a small ~4kD peptide called β-Amyloid surrounded by 
reactive microglia and astrocytes(Selkoe 1991; LaFerla and Oddo 2005).Most of the 
amyloid beta found in the neuritic plaques is the slightly longer Aβ42 which is more 
hydrophobic and therefore prone to aggregation. The neurofibrillary tangles are 
bundles of abnormal fibers found in the perinuclear cytoplasm. These fibers consist of 
~10 nm helical filaments composed of the microtubule-associated protein tau 
(Grundke-Iqbal, Iqbal et al. 1986; Kosik, Joachim et al. 1986; Selkoe 1991).The 
amyloid cascade hypothesis, the leading hypothesis for AD, states that misregulation 
of APP metabolism leads to the accumulation of Aβ42 which initiates AD 
pathogenesis. Accumulation and aggregation of Aβ42 would therefore lead to further 
pathological changes, including the formation of neurofibrillary tangles and synaptic 
loss and neuronal death and eventually dementia (Hardy and Allsop 1991; Tanzi and 
Bertram 2005). Ever since Aβ was identified as the first main component of amyloid 
plaques(Glenner, Wong et al. 1984), considerable experimental evidence has been 
reported suggesting Aβ as the primary pathological marker in AD and thereby 
supporting the amyloid cascade hypothesis.   
        The Aβ peptide is a part of and generated from a much larger β-amyloid 
precursor protein (APP) which is a type I integral membrane protein with a relatively 
large extracellular domain, a small intracellular domain and a membrane spanning 
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transmembrane segments (De Strooper and Annaert 2000). The APP gene is located 
in the long arm of chromosome 21. Regulated intramembrane proteolysis of APP by 
specific proteases (secretases) produce different fragments, including the Aβ peptide.  
 
AMYLOID BETA PRECURSOR PROTEIN:  
         In mammals APP is a member  of a larger gene family that includes APP-like 
proteins, APLP1 and APLP2 (De Strooper and Annaert 2000). Homologs of APP are 
also found in non-mammals like C.elegans (Apl-1) (Daigle and Li 1993) and 
Drosophila (APPL) (Martin-Morris and White 1990).  APP protein is a type 1 integral 
transmembrane protein with a large extracelluar domain and a relatively shorter 
intracellular domain (Annaert and De Strooper 2002). APP gene contains 19 exons, of 
which exons 7, 8 and 15 are alternatively spliced to produce at least 8 different splice 
variants of APP mRNA, of which APP695, APP751 and APP770 are the most 
predominant isoforms. APP751 and APP770 have an additional 56 amino acid domain 
(KPI domain) which is functionally and structurally related to the Kunitz-type serine 
proteinase inhibitors (Ponte, Gonzalez-DeWhitt et al. 1988). The APP protein is 
ubiquitously expressed in all cells, with the different splice variants displaying tissue 
specificity. Of particular importance here is that the APP695 isoform, which lacks the 
KPI domain, is predominantly expressed in neurons while the APP751 and APP770 are 
more expressed in non-neuronal cells (Sisodia, Koo et al. 1993; Zheng and Koo 
2006). All the three isoforms have the same Aβ domain, transmembrane and 
intracellular domain and are thus potentially amyloidogenic.  
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       All the isoforms of APP undergo maturation by N- and O- glycosylation of their 
extracellular / luminal domains during their secretory pathway transit from the 
Endoplasmic Reticulum to the Plasma Membrane. The N-glycosylation of APP 
occurs in the endoplasmic reticulum and the cis golgi and this APP is referred to as 
immature APP which does not undergo proteolysis by the various secretases (Tomita, 
Kirino et al. 1998). The immature APP then undergoes O-glycosylation in the medial 
and Trans Golgi (Figure 1-1). Once APP is both N- and O-glycosylated it is then 
referred to as mature APP and is now able to undergo proteolytic processing by the 
various secretases. Only a fraction of the mature APP is present at the plasma 
membrane where it is processed at the cell surface by α-secretase. In non-neuronal 
cell, APP is internalized within minutes of its arrival to the cell surface and delivered 
to the endosomes. β-secretase/BACE-1 which is localized in the late golgi and 
endosomes can cleave APP during its endocytosis from the cell surface, if the- 
secreatase cleavage has not occurred first. α- and β-secretase cleavage is followed by 
the γ-secretase cleavage in the transmembrane domain of APP (Koo and Squazzo 
1994; Small and Gandy 2006; Thinakaran and Koo 2008). Thus generation of Aβ is 
closely related to APP trafficking in the cell, especially in neurons since high level of 
neuronal expression of BACE-1 preferentially leads to APP being channeled through 
the amyloidogenic processing pathway (Thinakaran and Koo 2008). (Muresan, 
Varvel et al. 2009) showed that APP is transported in neurites as already cleaved 
polypeptide rather than full length protein. This indicates that in neurons the 
proteolytic cleavage of APP occurs first and the cleaved fragments then segregate into 
different vesicles that reach different destinations (Figure 1-2). Cleavage of mature 
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APP by either α- or β- secretases produces three different C-terminal fragments. C99 
and C89 are products of β- secretase cleavage whereas C83 is a result of the α-
secretase cleavage (Selkoe 1991; Selkoe 1998). The C-terminal or intracellular 
domain of APP contains various phosphorylation sites and functional motifs which 
play an important role in regulating its metabolism, trafficking and 
function(Thinakaran and Koo 2008). 
      A number of physiological roles have been suggested for APP but its actual 
functions remain unclear. Studies done on APP fragments that contain the KPI 
domain indicate that  APP could inhibit some serine proteinases involved in the blood 
coagulation pathway therefore suggesting that APP might play a regulatory role in the 
pathway(Smith, Higuchi et al. 1990; Van Nostrand, Schmaier et al. 1990; Van 
Nostrand, Wagner et al. 1990). APP is also suggested to play a role in various 
physiological processes like cell proliferation, cell survival, neuroprotection, memory 
enhancement, neuronal excitement and regulation of synaptic plasticity (Ma, Bagnard 
et al. 2008; Thinakaran and Koo 2008). Consistent with the above mentioned trophic 
functions of APP, studies have also shown that APP deficient mice have reduced 
synaptic markers correlating with learning deficits and decreased synaptic plasticity 
(Dawson, Seabrook et al. 1999). Studies have also shown APP to be involved in 
regulating presynaptic expression of choline transporter (Wang, Yang et al. 2007). 
Loss of APP has been shown to lead to aberrant localization of the choline transporter 
to neuromuscular junctions (Wang, Yang et al. 2007).This function is shown to be 
evolutionary conserved, as loss of APLP in Drosophila larvae results in decreased 
synaptic boutons in neuromuscular junctions of Drosophila(Ashley, Packard et al. 
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2005). These findings therefore suggest that APP might play an important role in the 
development of the nervous system and maintaining synapse structure and function. 
 
REGULATED INTRA MEMBRANE PROTEOLYSIS OF APP: 
      APP is subject to proteolytic processing by different sets of enzymes. 
Approximately 90% of APP is processed by the non-amyloidogenic pathway and 
remaining 10% undergoes processing by the amyloidogenic pathway. However this 
ratio can undergo a change due to certain mutations, environmental factors and age of 
an individual.  
     APP is thought to undergo proteolytic processing either in the secretory pathway 
after undergoing maturation, on the plasma membrane or in the endocytotic cycle. It 
is cleaved by three different secretase enzymes: α-, β- and γ-secretase(Suzuki, Araki 
et al. 2006) (Figure 1-3). The first proteolytic cleavage is by the α-secretase and it 
cleaves APP N-terminal to the trans-membrane domain at amino acid 17 of the NH2-
extracellular domain of APP (Figure 1-4). This cleavage releases a large soluble 
ectodomain fragment called s-APPα into the extracellular space and results in the 
retention of a membrane bound COOH-terminal fragment called C83(Esch, Keim et 
al. 1990). Since α-secretase cleaves within the Aβ of APP, cleavage by α-secretase is 
said to preclude the formation of Aβ. The membrane bound C-83 domain of APP is 
subsequently cleaved by another secretase called the γ-secretase to generate a 22-24 
amino acid (~3kD) residue called the p3 which is non-amyloidogenic and is released 
in the extracellular space and a 57-58 C-terminal residue APP intracellular domain 
(AICD) (Sisodia, Koo et al. 1990; Passer, Pellegrini et al. 2000). Alternatively during 
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non-amyloidogenic APP processing, the initial cleavage of APP can be carried out by 
β-secretase which cleaves at N-terminus of, the Aβ domain at amino acid 16 of APP 
releasing a soluble fragment s-APPβ into the extracellular space and retaining a 
membrane bound COOH-terminal 99 amino acid fragment C99 that begins at residue 
1 of the Aβ region(Seubert, Oltersdorf et al. 1993). Subsequent cleavage of the 
membrane bound C99 by γ-secretase results in the generation of multiple peptides the 
most common being Aβ40 and Aβ42, and also results in a C-terminal AICD fragment. 
Aβ40 comprises of approximately ~90% of the secreted Aβ in contrast to Aβ42 which 
is only 10% of the total secreted Aβ  (Seubert, Oltersdorf et al. 1993). In spite of this 
difference, Aβ42 is still the most predominant species found in plaques in AD patients. 
This could be because Aβ42, once generated, can form insoluble amyloid aggregates 
more rapidly than Aβ40 (Jarrett, Berger et al. 1993; Seubert, Oltersdorf et al. 1993). 
Exactly where APP undergoes regulated intra-membranous proteolysis is still under 
debate. However studies have shown that most of the s-APPα is by α-secretase 
occurring on the APP at the plasma membrane (Sisodia, Koo et al. 1990). It has also 
been shown that s-APPα can also be produced during the secretory intracellular 
trafficking of APP (De Strooper, Umans et al. 1993). 
     AICD once generated, translocates to the nucleus where it plays an important role 
in regulating transcription of various genes (De Strooper and Annaert 2000; Cupers, 
Orlans et al. 2001; Kienlen-Campard, Tasiaux et al. 2008). The γ-secretase complex 
therefore not only plays an important role in Aβ production but also controls AICD 
mediated intracellular signaling which in turn might be responsible in regulating 
expression of genes involved in the disease.  
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     AICD contains the 682YENPTY687 motif that is required for its interaction with 
several cytoplasmic proteins termed at APP adaptor proteins (Ando, Iijima et al. 
2001). In previous studies it was shown that the 682YENPTY687 motif of AICD is 
required for the interaction with Fe65 (Borg, Ooi et al. 1996). Phosphotyrosine 
interaction domains (PI domains) of Fe65, Fe65-like Fe65L1, Fe65L2, X11, X11-like 
X11L, X11L2 and mammalian disabled-1 (mDAB1) interact with this motif (Fiore, 
Zambrano et al. 1995; Borg, Ooi et al. 1996; Ando, Iijima et al. 2001). The AICD 
sequence also contains eight potential phosphorylation sites of which seven sites 
(Y653, S655,T668, S675,Y682, T686 and Y687) were reported to be phosphorylated 
in the brains of AD patients (Lee, Kao et al. 2003). It has been shown that 
phosphorylation of AICD at specific sites affects its interaction with the cytoplasmic 
adaptor proteins, in particular Fe65. Phosphorylation of AICD at Y682 residue was 
shown to decrease binding of Fe65 and X11 (Zambrano, Bruni et al. 2001) while 
phosphorylation at T668 is necessary for Fe65 binding to AICD and is required for 
AICD mediated transcriptional activation of various genes (Chang, Kim et al. 2006). 
Studies have shown that inhibition of T668 phosphorylation of AICD reduces its 
nuclear translocation and thereby it’s transcriptional activity (Kinoshita, Whelan et al. 
2002; Chang, Kim et al. 2006). Fe65 also has the ability to interact with several other 
proteins, on of them being TIP60 (TAT-interacting protein) resulting in the formation 
of the AICD-Fe65-TIP60 complex that then translocates to the nucleus stimulation 
transcription of specific genes (Cao and Sudhof 2001; Yang, Cool et al. 2006). This 
property of AICD has been used to monitor APP proteolysis and for identification of 
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putative regulators of APP metabolism by monitoring AICD production in cell 
culture (Zhang, Khandelwal et al. 2007).  
     Studies have implicated AICD to be involved in regulating transcription of various 
genes, one of them being GSK-3β encoding the enzyme glycogen synthetase kinase -
3β(Kim, Kim et al. 2003) which plays a key role in the pathogenesis of Alzheimer’s 
disease, Huntington’s disease, and bipolar disorder(Jope and Johnson 2004). AICD 
was also shown to induce expression  of other genes including KAI1, the metastasis 
suppressor gene (Baek, Ohgi et al. 2002); BACE and Neprilysin involved in Aβ 
homeostatsis (Kim, Kim et al. 2003); HES1 involved in differentiation and EGFR, 
ACE1, ACE2 and LFP1 involved in thymidylate synthetase (Muller, Meyer et al. 
2008). Therefore since AICD also regulated genes involved in AD pathogenesis it can 
be hypothesized that AICD many be an important contributing factor to the AD 
phenotype.  
 
α-SECRETASE:  
        In the non-amyloidogenic pathway APP is cleaved by the enzyme α-secretase 
between residues Lys612-Leu613 (Figure 1-4) (Allinson, Parkin et al. 2003) within the 
Aβ domain and this precludes the formation of Aβ. This cleavage also releases the 
large ectodomain of APP which seems to have neuroprotective and memory 
enhancement effects (Mattson, Guo et al. 1999). This cleavage can occur either in the 
late Golgi compartment (De Strooper and Annaert 2000) or at the plasma membrane 
in microdomains known as caveolae(Ikezu, Trapp et al. 1998). Studies have shown 
that pharmacological compounds like 1, 10 phenenthroline, batimastat (BB94) and 
 12
TAPI-2 inhibit sAPPα secretion in the cell culture medium in a variety of cell lines 
(Roberts, Ripellino et al. 1994; Parvathy, Hussain et al. 1999). It has also been shown 
that activation of muscarinic and epidermal growth factor receptors increase APP 
cleavage by α-secretase. Also activation of secondary messengers such as protein 
kinase C, tyrosine kinases and mitogen activated protein kinases (Mills and Reiner 
1999; Allinson, Parkin et al. 2003) result in increased sAPPα secretion and a 
significant decrease in Aβ formation (Jacobsen, Spruyt et al. 1994). Previous research 
indicates that various members of the ADAM (a disintegrin and metalloproteinase) 
family of proteins together act as α-secretase. These include ADAM 9, ADAM10 and 
ADAM 17(Moss, Jin et al. 1997; Primakoff and Myles 2000). ADAMs, like APP, are 
type I transmembrane protein with a N-terminal signal peptide, followed by a pro-
domain containing a “cysteine switch”. The pro-domain is followed by  a cleavage 
site for prohormone convertase, a catalytic domain with the HECH zinc binding 
motif, a cysteine rich disintegrin domain, next to which is a transmembrane domain 
which finally is followed by a short cytoplasmic domain(Allinson, Parkin et al. 2003).   
       ADAM17 also known as TACE (tumour necrosis factor –α-secretase) was first 
identified as a protease that cleaves and releases TNF-α from its membrane bound 
TNF precursor (Moss, Jin et al. 1997; Black and White 1998). It was shown that in 
cells derived from TACE knockout mice the regulated phorbol-ester induced release 
of sAPPα was deficient. This implied that TACE is involved in phorbol ester 
stimulated α-secretase activity(Buxbaum, Oishi et al. 1992). TACE belongs to the 
ADAM family of proteins and was shown to be involved in neurogensis and axonal 
extension in D. melanogaster (Rooke, Pan et al. 1996). Various studies have shown 
 13
that over expression of ADAM10 in cell lines not only increase α-secretase cleavage 
of APP, but endogenous activity of  α-secretase can also be inhibited by a dominant 
negative form of ADAM10 which has a mutation in the catalytic site (Lammich, 
Kojro et al. 1999; Lopez-Perez, Zhang et al. 2001). These studies strongly support the 
role of ADAM10 in α-secretase cleavage of APP. Strong support also comes from in 
vivo studies that show significantly reduced ADAM 10 protein levels in platelets and 
cerebrospinal fluid of AD patients (Colciaghi, Borroni et al. 2002). On the other hand, 
ADAM9 knockout mice did now show any major abnormalities during development 
or adult life. Also Aβ production and α-secretase cleavage in the hippocampal 
neurons from these mice was not significantly different than wild type 
mice(Weskamp, Kratzschmar et al. 1996). Therefore the involvement of ADAM9 as a 
α-secretase component is not very convincing but it may have a more significant role 
in α-secretase cleavage of APP which could be cell type dependent or activated under 
certain physiological conditions. However a study using over-expression as well as 
endogenous knockdown of TACE, ADAM10 and ADAM9 in a human cell line 
showed that all the three enzymes are equally involved in α-secretase cleavage of 
APP (Asai, Hattori et al. 2003). 
 
β-SECRETASE: 
       The enzyme β-secretase is an aspartic protease cleaves at the N-terminus of the 
Aβ sequence of APP and is the first prerequisite cleavage in the generation of Aβ.  β-
secretase cleaves APP at residue Asp596 (Citron, Teplow et al. 1995)and the β’ site at 
residues Glu606(Vassar, Bennett et al. 1999). This cleavage by β-secretase is the rate-
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limiting step in Aβ production which generates a soluble sAPPβ fragment and two 
different C99 and C89 membrane bound fragments depending on the site of cleavage. 
The C99 and C89 fragments can further be cleaved by the intramembranous γ-
secretase to produce Aβ. Although β-secretase activity was observed in most body 
tissues, highest activity was observed in neural tissue and neuronal cell lines (Haass, 
Schlossmacher et al. 1992; Seubert, Oltersdorf et al. 1993; Vassar, Bennett et al. 
1999). The BACE family of proteins includes two highly homologous transmembrane 
aspartly proteases BACE1 and BACE2 both of which exhibit β-secretase activity 
(Saunders et al. 1999). Unlike BACE1, BACE 2 cleaves APP between amino acids 
Phe614 and Phe615 of APP adjacent to the α-secretase cleavage site (Sun, He et al. 
2006). Since this cleavage occurs within the Aβ sequence of APP, it abolishes Aβ 
production. This suggested that BACE1 is the major β-secretase responsible for the 
generation of Aβ in the brain (Farzan, Schnitzler et al. 2000; Cole and Vassar 2008).  
      After synthesis in the endoplasmic reticulum, BACE1is transported to the golgi 
via the secretory pathway where it is processed by furin like proprotein convertase to 
remove the propeptide domain and further complex glycosylation leads to maturation 
of a 70kD BACE1(Haniu, Denis et al. 2000; Vassar 2004). In vivo studies indicate 
that BACE1 is transported down the axons and co-localized with the presynaptic 
markers (Sheng, Price et al. 2003; Zhao, Fu et al. 2007). It has been shown that 
BACE1 displays a high affinity for APP that contains and Swedish mutation (Lys595to 
Asn and Met596 to Leu) near the BACE1 cleavage site on APP. This mutation is 
known to cause familial form of AD by enhancing the β-secretase cleavage of APP 
resulting in more Aβ production (Citron, Oltersdorf et al. 1992).  
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 Mouse models recapitulating key features of AD pathology have been used to 
examine the function of BACE1 in vivo. It has been shown that mice with targeted 
BACE 1 knockout in their brain show no β-secretase activity and also do not show 
any adverse phenotype except hypo-myelination of both central and peripheral 
nervous system axons, indicating that BACE1 absence is relatively well tolerated in 
vivo in model organisms (Luo, Bolon et al. 2001). It has also been shown that 
transgenic mice over expressing APP bearing the Swedish Mutation (Tg2576) 
produce more Aβ and age dependent brain Aβ plaque formation along with 
pronounced memory deficits (Hsiao, Chapman et al. 1996). Another study showed 
that Tg2576 mice with complete BACE1 knockout failed to develop Aβ plaques 
(Laird, Cai et al. 2005) thereby proving that BACE1 is essential for Aβ production 
and is the main β-secretase responsible for brain plaque formation. Given these 
findings which suggest an important role of BACE1, it can be understood that 
BACE1 can be a prime target for treatment of AD.  
 
γ-SECRETASE:  
        The γ-secretase enzyme cleaves APP after it has been cleaved by either the α- 
secretase or β-secretase. Cleavage of APP by α- secretase or β-secretase leads to the 
production of sAPPα or sAPPβ which are released in the extracellular matrix and  
CTFα or CTFβ which remain membrane bound. Both the membrane bound CTF are 
then subsequently cleaved within their transmembrane domain by the γ-secretase to 
produce p3 from CTFα and Aβ from CTFβ. In addition, this cleavage also produces 
AICD from either CTFα and  CTFβ, which then translocates into the nucleus and 
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plays a role in activating gene transcription (as discussed above). The γ-secretase 
enzyme is a multimeric complex composed of four proteins, Presenilin1(PS1), Pen-2, 
Aph-1 and Nicastrin (NCT) (Figure 1-5).  
           Other than BACE1, another major clue to AD pathology came from the 
discovery of two related genes, PS1 and PS2. Mutations in both these genes, which 
are a part of the γ-secretase complex, are associated with early onset Alzheimer’s 
disease (Levy-Lahad, Wasco et al. 1995; Bruni 1998). More than 100 missense 
mutations have been identified so far in these genes and all the mutations lead to the 
production of Aβ42, the more aggregration prone form of Aβ (Tanzi and Bertram 
2005), indicating that the Presenilin mutations change the cleavage site specificity of 
γ-secretase. Also it was shown that knockout of PS1 in mice reduces the γ-secretase 
activity leading to almost a complete loss of Aβ peptide generation. This provided the 
first evidence that presenilins are an important part of the γ-secretase complex(De 
Strooper, Saftig et al. 1998). Presenilins are membrane embedded aspartyl proteases 
with nine transmembrane domains. The protein can be proteolytically cleaved to 
produce a N-terminal (NTF) and C-terminal fragment (CTF)(Thinakaran, Borchelt et 
al. 1996). The active site for the γ-secretase lies between the interface of the NTF and 
CTF as indicated by studies which affinity labeled reagents directly bound to the NTF 
and CTF identifying the interface between them as the catalytic site of the protease 
(Li, Xu et al. 2000). 
       After the discovery of PS1, the other component of the complex to be discovered 
first was Nicastrin which is a presenilin interacting protein. Nicastrin is a 120-140kD 
glycosylated type1 integral membrane protein with almost the entire protein being 
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extracellular (Wolfe 2006). Nicastrin knockdown experiments indicated that along 
with presenilin, nicastrin was also important for APP cleavage by γ-secretase (Yu, 
Nishimura et al. 2000). Further studies in C.elegans identified two new gene Aph-1 
and Pen-2(Francis, McGrath et al. 2002). Aph-1 is a transmembrane protein with 
seven transmembrane domains and the C-terminus located in the cytoplasm(Fortna, 
Crystal et al. 2004). Pen-2 is a hairpin like structure protein with two transmembrane 
domains with both the amino and carboxy terminal located in the cytoplamic side 
(Crystal, Morais et al. 2003). Over expression of all the four proteins (PS1, Pen2, 
Aph-1 and Nct) together resulted in increased γ-secretase activity(Takasugi, Tomita 
et al. 2003). Also in addition co-immunoprecipitation of any one of the proteins 
brought down all the others indicating that all the four proteins of the complex 
interact with each other(Kimberly, LaVoie et al. 2003). There are six variants of the 
γ-secretase complex which exist due to different combinations of the two presenilins 
and three different Aph-1 proteins. The different complexes formed have different 
affinities for different γ-secretase substrates which include not only APP and Notch 
but also APP-like protein APLP-1, APLP-2, Notch2-4, ErbB4, E- and N-Cadherins 
and CD44 receptor (Kopan and Ilagan 2004). It has also been shown that γ-secretase 
complex containing PS-2 has lower proteolytic activity than PS-1 containing complex 
(Lai, Chen et al. 2003). 
        The γ-secretase complex assembles at the endoplasmic reticulum soon after 
translation and membrane insertion. Immature, hypoglycosylated Nicastrin and Aph-1 
assemble into a subcomplex followed by Presenilin and Pen-2 (Gu, Chen et al. 2003). 
It has been shown that knockdown of Pen-2 does not lead to Nicastrin-Aph-1 and 
 18
Presenilin complex formation. Addition of Pen-2 to the complex leads to production 
of the NTF and CTF via endoproteolysis of  Presenilin, maturation of Nicastrin and 
therefore active γ-secretase complex (Watanabe, Tomita et al. 2005). When the 
assembly is completed, the γ-secretase complex traffic’s to its functional sites in the 
plasma membrane.  
 
Aβ METABOLISM: 
        The Aβ peptide plays a central role in AD. Since APP is ubiquitously expressed 
these Aβ peptides can be produced in cells , that express BACE1, by the proteolytic 
cleavage of APP by two aspartyl proteases referred to as the β- and γ-secretases 
(Haass, Schlossmacher et al. 1992). Depending on where γ-secretase cleaves CTFβ, 
three different isoforms of Aβ are produced, Aβ38, Aβ40, Aβ42. Of the three isoforms 
of Aβ produced, Aβ42 is particularly crucial, since it has been shown to oligomerize 
quickly and form fibrils significantly faster than Aβ40, therefore being termed to be 
more amyloidogenic than Aβ40(Jarrett, Berger et al. 1993).  
      Aβ is a natural product of APP processing and is present in the brain and CSF of 
normal healthy individuals throughout life. There the mere presence of Aβ does not 
cause neurodegeneration and AD. Neurodegeneration in AD is therefore hypothesized 
to be caused by oligomerization due to self association of  these Aβ peptides resulting 
in synaptic dysfunction and loss(Walsh, Tseng et al. 2000). Although Aβ peptides of 
various lengths are found to accumulate in plaques, the longer Aβ42 is the more 
prominent peptide species in these aggregations(Roher, Lowenson et al. 1993). It was 
later reported that Aβ levels increased 2-3 times in human APP695 mice and PDAPP 
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mice with the APP717 mutation compared to control mice (Games, Adams et al. 
1995; Hsiao, Chapman et al. 1996). Follow up studies reported mutations in APP 
increased Aβ42  production over other Aβ species(Suzuki, Cheung et al. 1994; 
Scheuner, Eckman et al. 1996). Most of the studies done on human brain tissue not 
only show an increase in the amount and aggregation of Aβ42 in AD brains compared 
to control brains but also show a significant increase of insoluble Aβ40 in sporadic 
AD brain tissue (Naslund, Schierhorn et al. 1994; Tamaoka, Fukushima et al. 1996; 
Hosoda, Saido et al. 1998; Lue, Kuo et al. 1999; Verdile, Gnjec et al. 2004; Gregory 
and Halliday 2005). It has also been shown that in a non-AD rat model, Aβ oligomers 
isolated from the cerebral cortex of AD subjects. These oligomers inhibited long-term 
potentiation (LTP), enhanced long-term depression (LTD) and reduced dendritic 
spine density in normal rodent hippocampus(Shankar, Li et al. 2008). This supports 
the hypothesis that increase in Aβ levels increase their insolubility leading to their 
dimerization and aggregation which has significant pathogenic effects in the brain.  
      The ‘amyloid cascade’ hypothesis states that the increase Aβ burden in the brain 
is the primary pathogenic event in  AD and argues that the neurodegenerative disease 
process is a consequence of the imbalance between the generation and clearance of 
the Aβ peptide (Hardy and Allsop 1991). Aβ clearance can occur through three 
pathways, extracellular proteolysis by degrading enzymes(Selkoe 2001), transport 
across the blood brain barrier or receptor mediated endocytosis (Zlokovic 2004). Two 
major zinc metalloendopeptidases called the insulin degrading enzyme (IDE) and 
neprilysin (NEP) are the main endopeptidases involved in Aβ degradation. It was 
convincingly shown that IDE knockout mice have increased endogenous levels of Aβ 
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and AICD in the brain and primary neuronal cultures from these mice are show less 
effective degradation of radiolabelled Aβ in vitro (Farris, Mansourian et al. 2003).  
Neprilysin is another peptidase responsible for the degradation of Aβ. A recent study 
showed that intracerebral injection of a NEP lentiviral vector in a transgenic mouse 
model of cerebral amyloidosis resulted in a 50% decrease in the cortical amyloid 
deposits (Marr, Rockenstein et al. 2003). This was by far the only study that 
demonstrated a degradation effect by NEP on a preexisting Aβ accumulation.  
        Low density lipoprotein receptor related protein (LRP) plays a key role in 
exporting Aβ from the brain. It also binds to other ligands like apolipoprotein E 
(apoE), α2-macroglobulin(α2M), and APP(Tanzi, Moir et al. 2004). Antagonists to 
LRP have been shown to reduce Aβ clearance from the brain by approximately 90% 
in mice injected with radiolabelled Aβ (Shibata, Yamada et al. 2000). Cerebral Aβ 
load was increased in mice with low levels of LRP at the blood brain barrier due to 
knockout o the LRP chaperone protein RAP(Van Uden, Mallory et al. 2002). Aβ 
forms a complex with the LRP ligands like α2M and apoE. This complex then binds 
with the LRP and the LRP-ligand complexes are then internalized to late endosomes 
and are then either delivered to the lysosomes for degradation or transcytosed across 
the blood brain barrier into the plasma(Kang, Pietrzik et al. 2000; Tanzi, Moir et al. 
2004) 
      There is also some evidence which suggests the role of Insulin growth factor-1 in 
Aβ clearance. Down regulation of the Insulin growth factor (IGF-I) in the aging brain 
was proposed to decrease the clearance of Aβ.  This involves the insulin receptor 
cascade which can also increase amyloid toxicity. IGF-1 therefore may modulate the 
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levels of insulin degrading enzyme in the brain, altered levels of which could lead to 
Aβ accumulation(Messier and Teutenberg 2005). 
        Even though Aβ accumulation can occur due to an imbalance between its 
anabolism and catabolism, the overproduction of Aβ can occur solely due to 
increased APP protein production. This might occur due to genetic causes or 
misregulation of APP gene expression both of which have been shown to increase Aβ 
production increasing the risk of causing early onset AD (Beyreuther, Pollwein et al. 
1993; Rovelet-Lecrux, Hannequin et al. 2006). 
 
APP GENE REGULATION: 
       In Alzheimer’s disease, the levels of Aβ and that of the factors involved in its 
production and deposition play an important role in the neuropathogenesis of AD. 
Regulation of transcription on these various AD causing genes may be important in 
the neurodegenerative process. The most important component of the molecular 
etiology of Alzheimer’s Disease may lie in the expression of APP since the amount of 
Aβ produced will depend on the amount of APP present at the site to undergo 
proteolysis via the amyloidogenic pathway. Evidence is accumulating that an increase 
in the expression of the APP gene, which encodes the APP protein, can increase the 
risk for Alzheimer’s disease by increasing the production of the pathogenic Aβ-42. 
Not only missense mutations at or near the β or the γ-secretase (De Strooper and 
Annaert 2000) cleavage sites of APP and in the presenilins, but it was also shown in 
different studies that Aβ production also depended on the amount of APP substrate 
available for proteolysis(Podlisny, Lee et al. 1987; Beyreuther, Pollwein et al. 1993; 
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Sleegers, Brouwers et al. 2006). Therefore an increased expression of the APP gene 
itself can cause an increase in the production of Aβ42 and subsequent Aβ deposition. 
Thereby regulation of APP gene expression plays a critical role in controlling the 
amount of APP protein produced and the levels of Aβ. 
        APP is ubiquitously expressed with the highest expression in neuronal cells of 
the CNS(Goedert 1987). To understand APP transcription studies have shown that the 
APP promoter is similar to housekeeping genes lacks a canonical TATA box and had 
a GC-rich region which contains numerous binding sites for various putative 
transcription factors (Lahiri, Ge et al. 2005). 70% of APP promoter activity was 
shown to be regulated by binding of the CCCTC-binding factor which is also a 
known regulator of c-myc which is implicated in apoptosis(Vostrov and Quitschke 
1997). Another transcription factor studied to bind the APP promoter to regulate its 
transcription was the Sp1 transcription factor whose binding site overlaps with the 
binding site of another transcription factor CA1. Studies in rat brains have detected 
low Sp1 expression in different brain regions thereby suggesting CA1 to be the major 
regulator of APP in neural cells. Therefore it is hypothesized that deregulated APP 
over expression might be due to a local increase in brain Sp1 activity (Beyreuther, 
Pollwein et al. 1993). APP promoter is also know to bind various other transcription 
factors like HSF-1 which in increases APP transcription in response to stress(Dewji 
and Do 1996) and members of the NF-κB/Rel family which act as APP regulators in 
cells of neuronal origin(Grilli, Ribola et al. 1995). The promoter of APP is highly 
homologous to rodents and primates. They all have the GC rich region and lack the 
TATA and CAAT boxes and also share most of the above mentioned transcription 
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factor binding sites(Chernak 1993).This suggests that these factors play a major role 
in regulating APP regulation in vivo. An imbalance in this regulatory mechanism 
caused by mutation in the APP promoter or by altered expression of the transcription 
factors in the brain might be a risk factor for the development of AD (Beyreuther, 
Pollwein et al. 1993; Theuns and Van Broeckhoven 2000).  
       More recently it has been shown that genetic variants in the 5’ UTR of APP 
increased APP transcription in neuronal cells were associated with the disease 
(Brouwers, Sleegers et al. 2006). An extensive mutation analysis was done on the 
APP promoter in a large group of well documented Belgian patients. This analysis of 
the APP promoter region leads to the identification of six genetic variants in AD 
patients only. Three of these six variants (118C to A, 369C to G and 534 G to A) 
showed a significant ~ 2-3 fold increase in neuron specific increase of APP 
transcription (Brouwers, Sleegers et al. 2006). This level of APP expression is also 
shown to influence the onset age of AD in mutation carriers by increasing the risk for 
Early Onset AD. 
        In addition to the identification of APP 5’ regulatory sequence involved in APP 
transcriptional control, its has also been shown that local inflammation at the site of 
the developing plaques in the brain is important to AD pathogenesis (Goldgaber, 
Harris et al. 1989; Dinarello 1996). Epidemiological studies identifying traumatic 
brain injury as a risk factor for AD strengthen the hypothesis that inflammatory 
mechanisms contribute to the disease pathogenesis.(Roberts, Gentleman et al. 1991)  
Interleukin -1 (IL-1) is the first pro-inflammatory cytokine secreted after activation of 
macrophage cells in the brain after brain injury (Dinarello 1996). IL-1 is expressed 
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abundantly in microglia around developing plaques in brain cells.(Griffin, Stanley et 
al. 1989).  A study demonstrated that increase in APP induced by IL-1 was blocked 
by an inhibitor of protein kinase C(Nishizuka 1988). Therefore a protein kinase C 
dependent pathway has linked IL-1 to a 3 fold increase in APP gene expression at the 
level of enhanced translation (Goldgaber, Harris et al. 1989). A novel 90 nucleotide 
IL-1 responsive element was identified in the 5’UTR of APP gene which increased 
synthesis of APP by IL-1 (Rogers, Randall et al. 2002). Also over-expression of IL-1 
by microglia in response to traumatic head injury has been shown to increase the risk 
for Early Onset AD. (EOAD) (Sheng, Ito et al. 1996).Therefore enhanced translation 
of APP mRNA by IL-1 provides a mechanism by which IL-1 increased the risk for 
AD and influences AD pathogenesis.  
        Some other studies have also examined the coding region of APP to show that 
certain sequences in this region also regulate APP synthesis by regulating APP 
translation. One such protein which mediates translation of APP through sequences in 
the coding region of APP mRNA is the FMRP (Fragile X mental retardation protein). 
FMRP is an mRNA binding protein that is ubiquitously expressed throughout the 
body. It is required for type 1 metabotropic glutamate receptor (mGluR) dependent 
translation of synaptic proteins by binding to putative G-quartets in the coding 
sequences of the mRNAs for those proteins(Schaeffer, Bardoni et al. 2001). Database 
searches have revealed that APP mRNA possesses a G-quartet like motif in the 
coding region (position 825-846) embedded within a guanine rich domain(Schaeffer, 
Bardoni et al. 2001). It has been shown that after stimulation with the mGluR agonist 
DHPG (Dihydroxyphenylglycol) APP levels increased significantly in wild type 
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cultured neurons from mouse. Also APP mRNA co-immunoprecipitated with FMRP 
in wild type cultured neurons but this interaction was lost with DHPG treatment. This 
indicates that FMRP repressed the translation of APP through mGluR dependent 
interactions with APP mRNA. Knockout of FMRP leads to constitutively elevated 
APP levels. Therefore FMRP acts as an immediate early response protein that 
regulates APP translation at the synapse. When FMRP is bound to APP mRNA 
translation is repressed. Upon mGluR activation FMRP is released from APP 
resulting in prompt APP protein synthesis (Westmark and Malter 2007). Mutations in 
the FMRP binding sequence in the coding region of APP mRNA or down-regulation 
of FMRP leads to increased translation of APP mRNA and increase APP synthesis 
thereby increasing the risk for AD. In addition FMRP mRNA and protein expression 
have been shown to be down-regulated in aging mouse brain (Singh, Gaur et al. 2007) 
suggesting that repressed transcripts such as APP mRNA would be up-regulated with 
aging and therefore increasing the risk for AD.  
       APP mRNA 3’UTR is another regulatory element, sequences in which, also 
regulate APP gene expression by modulating message stability and regulating 
message translation. A 29 nucleotide destabilizing element ~200 nucleotides 
downstream from the APP mRNA stop codon was identified to regulate the half life 
of APP mRNA(Rajagopalan and Malter 2000). These 29 nucleotides maintain the 
half life of APP mRNA at ~ 4 hours. Mutations in this element resulted in substantial 
stabilization of APP mRNA increasing its half life to >12 hours and thereby a 2-4 
fold increase in APP synthesis (Rajagopalan, Westmark et al. 1998). It has also been 
proposed that APP mRNA stability is mediated by the regulated interaction of hnRNP 
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and nucelolin with the 29 nt element in APP 3’UTR. Binding of hnRNP and nucleolin 
to the 3’UTR blocked APP mRNA decay and increased its half life and enhanced its 
translation (Rajagopalan, Westmark et al. 1998). Therefore APP expression is also 
regulated post-transcriptionally by a 29 nucleotide element in the 3’UTR of APP 
mRNA which has a dramatic effect on APP synthesis. 
       Therefore in AD patients, while the number of APP gene is the same as that in 
normal subjects (Podlisny, Lee et al. 1987) the control of  transcription, translation 
and stability of APP mRNA could modify APP production without an additional copy 
of the APP gene. However it has also long been recognized that triplication of APP in 
patients with Down’s syndrome leads to AD symptoms early in life, 50 years earlier 
than the age of onset of AD compared to the normal population, through over-
expression of APP (Rumble, Retallack et al. 1989). In a more recent study it was 
found that genomic duplication of the APP locus in the absence of a full trisomy 21 
lead to Early Onset AD suggesting that increased expression of APP can increase AD 
risk by increasing AD pathology (Sleegers, Brouwers et al. 2006). Therefore 
increased expression of APP per se increases Aβ productions eventually leading to 
AD. 
   More recently it has been predicted that APP gene expression is also regulated by 
a unique class of non-coding RNA’s known as microRNA (miRNA) (John, Enright et 
al. 2004). A recent study showed that miRNA expression is differentially regulated in 
AD brains when compared to normal brains indicating that changes in miRNA 
expression profile may lead to increased APP synthesis, and thereby increased Aβ 
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production and plaque formation in AD brains(Lukiw 2007). Identification of these 
microRNAs will therefore provide new insights in regulating APP gene expression. 
 
MicroRNAs: BIOGENESIS 
         miRNAs are ~19-25 nucleotides long single-stranded RNA molecules which are 
generated from endogenous hairpin-shaped transcripts. miRNAs are one of the largest 
gene families comprising of ~1% of the genome(Ambros, Bartel et al. 2003; Bartel 
2004). Vertebrate genomes are predicted to encode as many  as 1000 unique miRNAs 
which are predicted to regulate expression of at least 30% of genes (Bartel 2004). 
miRNAs are important gene regulatory elements that function is post-transcriptional 
gene repression by base pairing to the 3’UTR ends of their target mRNAs. This leads 
to target mRNA translational repression or cleavage. The first miRNAs to be 
discovered were the regulatory RNAs Lin-4 and let-7 (Lee, Feinbaum et al. 1993) in  
C. elegans , where they were found to regulate the developmental timing in the 
organism. 
       Most of the microRNAs are located in the intergenic region but some are also 
found in the intronic regions of known genes in either the sense or antisense 
orientation. Most of the miRNAs approximately 50% are found in close proximity to 
other miRNAs and such miRNAs clusters might be transcribed from a single 
polycistronic transcription unit (Lagos-Quintana, Rauhut et al. 2001; Lau, Lim et al. 
2001). miRNA genes can also be grouped on the basis of their genomic locations. A 
recent analysis(Rodriguez, Griffiths-Jones et al. 2004) showed that 117 miRNA genes 
are intronic in the sense orientation, 90 are found in introns of protein coding genes 
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and 27 miRNAs are found in introns of non-coding RNAs. Since miRNAs expression 
is under elaborate control during development and in various tissues similar to other 
genes transcribed by RNA polymerase II it is believed that transcription of miRNA is 
also mediated by RNA polymerase II (Lau, Lim et al. 2001; Lagos-Quintana, Rauhut 
et al. 2002). However it is also possible that a small number of miRNA genes may be 
transcribed by RNA polymerase III. 
      microRNA maturation occurs part in the nucleus where miRNAs are first 
transcribed as long primary transcripts and subsequently cleaved into mature 
miRNAs. The remaining maturation part occurs in the cytoplasm after nuclear export 
of the precursor miRNA which is necessary for the cytoplasmic processing to take 
place. Transcription by RNA polymerase II yields primary miRNA (pri-miRNA) that 
are hairpin shaped and several kilobases long. This hairpin shaped structure is cleaved  
by the nuclear RNAase III Drosha to form a shorter precursor miRNA (pre-miRNA) 
with a short ~2 nucleotide 3’ overhang (Figure 1-6). Drosha is a large ~160 kD 
protein that is conserved in animals and contains a RNAse III domain and a RNA 
binding domain which are crucial for its activity(Lee, Ahn et al. 2003). Interaction of 
Drosha with its co-factor DiGeorge syndrome critical region gene 8 (DGCR8) forms 
the microprocessor complex. DGCR8 is believed to help Drosha  in substrate 
recognition(Lee, Ahn et al. 2003). Drosha microprocessor complex can measure the 
length of the stem of the hairpin pri-miRNA and cleave approximately two helical 
turns (~22 nucleotides)  from the terminal loop (Zeng and Cullen 2005). Pre-miRNAs 
that are generated after the Drosha cleavage are then exported to the cytoplasm for 
further processing in mature miRNAs. Cytoplasmic transport is followed by Dicer 
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processing which generates the final ~22 nucleotide product (Figure 1-6). Nuclear 
export occurs through nuclear pore complexes by one of the nuclear transport 
receptors, exportin-5 which recognizes the 3’ overhang in the pre-miRNA (Lund, 
Guttinger et al. 2004). Following cytoplasmic export, GTP is hydrolyzed to GDP to 
release the pre-miRNA from the export complex. Cells depleted of exportin-5 showed 
reduced levels of pre-miRNA and mature miRNAs with no pre-miRNA 
accumulation. This indicates that pre-miRNA are stabilized by their interaction with 
exportin-5(Bohnsack, Czaplinski et al. 2004). Following export of pre-miRNA to the 
cytoplasm, they are cleaves by the cytoplasmic RNAse III Dicer to generate ~22 
nucleotide miRNA duplexes (Hutvagner, McLachlan et al. 2001)(Figure 1-6). Dicer 
is a highly conserved, ~200 kD protein found in all eukaryotes with some organisms 
containing multiple homologs of Dicer. Apart from two RNAse III domain and a 
RNA binding domain, it also contains a DUF28 and PAZ domain. PAZ domain binds 
to 3’ protruding ends of small RNAs. The roles of other Dicer domains are unknown 
(Knight and Bass 2001; Yan, Yan et al. 2003). The double stranded ~22 nucleotides 
long, mature miRNAs generated by Dicer are then incorporated in complexes called 
‘miRISC’ (microRNA-containing RNA induced silencing complexes) (Figure 1-6). 
Studies using siRNAs indicate that the relative thermodynamic stability of the two 
ends of the duplex determines the strand to be incorporated into miRISC. The strand 
with a relatively unstable base pair at the 5’ end remains and the unselected strand is 
removed and degraded (Khvorova, Reynolds et al. 2003; Schwarz, Hutvagner et al. 
2003). The assembly for the miRISC complex and the incorporation of the miRNA 
into this complex is a dynamic process and usually coupled with pre-miRNA 
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processing by RISC, but the details are not very well understood(Rana 2007).  The 
major components of miRISC are the proteins of the Argonuate (AGO) family, which 
function in both miRNA and siRNA pathways. Mammals have four AGO proteins, 
AGO1 to AGO4, of which AGO2 functions in RNAi because it contains a RNAse H 
like P-element induced wimpy testis (PIWI) domain. Because of the presence of this 
domain AGO2 can cleave at the center of the siRNA-mRNA duplex. Apart from 
AGO2, miRISC also contains other proteins which function in miRISC assembly, or 
those which function in regulatory mechanism or effectors which mediate the 
repressive miRNP function (Peters and Meister 2007; Filipowicz, Bhattacharyya et al. 
2008). Examples are the FMRP protein (Fragile X mental retardation protein) and its 
D.melanogaster orthologue, dFXR both of which are RNA binding proteins known to 
act as translation modulators, particularly in neurons(Jin, Alisch et al. 2004). Some P-
body components like GW182 and RCK/p54 also interact with the AGO2 in miRISC 
and are essential in miRNA mediated gene repression (Behm-Ansmant, Rehwinkel et 
al. 2006; Chu and Rana 2006). 
       Several research groups have provided evidence that miRNA may act as key 
regulators of processes as diverse as early development (Reinhart, Slack et al. 2000) 
cell proliferation cell death (Brennecke, Stark et al. 2005) and cell differentiation 
(Dostie, Mourelatos et al. 2003). Recent studies of miRNA expression implicate 
miRNAs in brain development (Krichevsky, King et al. 2003) and Parkinson’s 
disease (Hebert and De Strooper 2007) suggesting possible links between miRNA 
and human diseases. There is a speculation that in higher eukaryotes the role of 
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miRNAs in regulating gene expression could be as important as that of transcription 
factors. 
 
MicroRNAs: MECHANISMS OF GENE REPRESSION: 
       miRNAs form imperfect base pairs with the 3’UTR of their target genes, with a 
stringent requirement of contiguous and perfect base pairing of the nucleotides 2-8 of  
the miRNA representing the ‘seed’ region, with its target sequence, which nucleates 
the interaction(Doench and Sharp 2004; Brennecke, Stark et al. 2005). microRNA are 
known to mediate gene repression by interfering with translation of their target genes. 
Translation can be broadly dived into initiation, elongation and termination, with 
multiple proteins being involved at each step. Available evidence indicates that 
miRNAs can repress translation either at the initiation step or at post initiation stage 
(Figure 1-7).  
       In vitro experiments in HeLa cells indicate that translation of m7-G capped 
mRNAs is repressed by miRNAs with no repression seen with mRNAs containing an 
IRES. This indicated that the m7-G cap was important for translation inhibition 
(Pillai, Bhattacharyya et al. 2005). Polysome gradient analysis of reporter mRNAs 
showed a marked shift in sedimentation towards the top of the gradient, indicating 
reduced ribosome loading on the repressed mRNA. This gave experimental support to 
the theory of miRNAs inhibiting translation at the initiation step (Bhattacharyya, 
Habermacher et al. 2006). Evidence also suggests that miRNA bound miRISC 
interferes with the eIF4E-eIF4G interaction or bind directly to the cap and hence 
prevent assembly of the 40S initiation complex(Cho, Poulin et al. 2005; Richter and 
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Sonenberg 2005). It was also reported that the central domain of AGO2 proteins 
contain sequence homology to eIF4E which is a cap binding protein. Mutations of 
amino acids in this domain prevented the interaction of AGO2 to the m7GTP-
Sepharose and prevented AGO2 from inhibiting translation(Kiriakidou, Tan et al. 
2007). This indicates that AGO2 and other proteins of miRISC can compete with 
eIF4E for m7G cap binding and prevent translation of capped mRNAs. 
Studies(Wang, Love et al. 2006; Wakiyama, Takimoto et al. 2007) in HEK293 cells 
showed that mRNAs with miRNA target sites underwent de-adenylation whether they 
contained a m7G cap or an IRES thereby suggesting that targeting either the m7G cap 
or the poly A tail miRNAs prevent the interaction between the 5’cap and 3’poly A 
tail. This disrupts the eIF4G mediated mRNA circularization leading to a translation 
block at the initiation stage. An alternate mechanism was also reported 
(Chendrimada, Finn et al. 2007) which showed that the eIF6 and 60s ribosomal 
subunit co-immunoprecipitates with the AGO2-DICER complex and depletion of 
eIF6 in C.elegans rescues mRNA targeting by miRNA. eIF6 which was thought to act 
as a translation initiation factor was later shown to be involved in the biogenesis of 
the 60S ribosomal subunit. It was proposed that AGO2 interacts with eIF6 and 
prevents the interaction of the 60s subunit with the 40s subunit to complete the 
translation initiation complex by eIF6 mediated targeting of 60s to 
miRISC(Chendrimada, Finn et al. 2007). 
      In spite of in vivo and in vitro evidence supporting translation initiation block by 
miRNA, it is unlikely that this is the only mechanism of miRNA mediated gene 
repression.  Studies in C.elegans have shown lin-14 and lin-28 mRNAs, which are 
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targets of lin-4 miRNA, to be associated with polysomes despite of a strong reduction 
in their protein levels (Olsen and Ambros 1999; Seggerson, Tang et al. 2002). Studies 
in mammalian cells also support the results seen in C.elegans. Reporter mRNAs, 
targeted by either synthetic or endogenous miRNAs, remain associated with active 
polysomes shown by the sensitivity of polysomes to  different conditions that inhibit 
translation(Petersen, Bordeleau et al. 2006). Therefore a ribosome drop off model is 
also proposed as a putative mechanism of miRNA mediated gene repression. This 
model suggests that miRNAs decelerate translation initiation by rendering  ribosomes 
to terminate translation prematurely. Another hypothesis also states that proteins are 
continually translated from repressed mRNAs associated with competent polysomes, 
but these proteins do not accumulate because they are rapidly degraded by the miRNP 
recruited proteases(Olsen and Ambros 1999). 
      Several reports suggest that miRISC proteins, miRNA and the target mRNAs all 
accumulate in discrete cytoplasmic foci called P-bodies or GW bodies (Liu, Valencia-
Sanchez et al. 2005; Pillai, Bhattacharyya et al. 2005; Sen and Blau 2005). P-bodies 
are known to be temporary storage sites for repressed mRNAs in yeast and mammals. 
Studies have shown are positive correlation between miRNA mediated translational 
repression and accumulation of target mRNAs into visible P-bodies(Liu, Valencia-
Sanchez et al. 2005; Bhattacharyya, Habermacher et al. 2006; Pillai, Bhattacharyya et 
al. 2007). Global inhibition of miRNA biogenesis significantly decreases the number 
and size of P-bodies in HeLa cells. Also the depletion of P-body components like 
GW182, Rck/p54, Dcp1, Dcp2 prevents effective repression of target mRNAs by 
miRNAs (Chu and Rana 2006; Pauley, Eystathioy et al. 2006). Most of the P-body 
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proteins are found in the cytosol. Hence it is possible the repression by miRISC is 
initiated in the cytosol and the repressed mRNAs then form P-body aggregates. P-
body proteins like RCK/p54, Pat1, and Rap55 have an already established role in 
translation inhibition at the initiation step (Tanaka, Ogawa et al. 2006). These 
proteins along with GW182 can be assisting in miRISC in inhibiting translation. 
Hence the role of P-body components in miRNA mediated gene repression can be 
explained by the conserved function of the P-body proteins in translation inhibition. 
This also suggests a model wherein these P-body proteins assemble into a repressive 
complex on the target mRNA after the miRNA binds to it, eventually leading to 
mRNA aggregation into P-bodies. More recently it has also been suggested that 
miRNA mediated repression can be reversed under certain conditions. In human 
hepatoma cells, CAT-1 mRNA is repressed by miR-122 and accumulated in P-bodies. 
Cells subjected to starvation or other type of stress, show a release of CAT-1 mRNA 
from P-bodies. This requires binding of a protein HuR to the 3’UTR of CAT-1 
mRNA. However this regulation is not specific for miR-122 and liver cells because 
reporters controlled by let-7 and containing HuR binding sites are upregulated in the 
same ways as CAT-1 mRNA in HeLa cells (Bhattacharyya, Habermacher et al. 
2006). Studies have shown that HuR moves to the cytoplasm from the nucleus in 
response to stress where is modulates translation, however the exact mechanism still 
remains unknown(Brennan and Steitz 2001) It has also been shown that in cultured 
rat neurons treatment of cells with BDNF stimulates LimK1 synthesis by relieving 
miR-134 mediated inhibition of LimK1 mRNA(Schratt, Tuebing et al. 2006). In spite 
of the given evidence, the exact mechanism of miRNAs mediated gene repression 
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still needs to be elucidated. Involvement of the P-body components in miRISC is 
more consistent with the theory of inhibition of translation initiation. Also since P-
bodies lack ribosome’s, it suggests that ribosome drop off would be required before 
the mRNA gets incorporated in the P-bodies. The role of P-bodies therefore also 
requires further investigation. 
 
microRNA AND ALZHEIMER’S DISEASE: 
        Alzheimer’s disease is a complex age associated neurodegenerative disorder 
characterized by the accumulation of extracellular deposits of amyloid plaques and 
intracellular neurofibrillary tangles(Tanzi and Bertram 2005).  The amyloid plaques, 
observed in AD brains arise from the accumulation of Aβ40 and Aβ42 after sequential 
cleavage of APP by β-secretase and γ-secretase. (Sisodia, Koo et al. 1990). Increase 
in neuritic plaques consisting of amyloid deposits and neurofibrillary tangles is 
believed to lead to synaptic loss, oxidative stress and formation of neurofibrillary 
tangles inside the neurons which result due to hyperphophorylation of microtubule 
associated protein tau(Hardy and Selkoe 2002; Johnson and Stoothoff 2004). In 
familial AD, the increase in amyloid plaques is caused due to mutation either in APP, 
or the genes that encode the enzymes involved in APP processing. However increased 
expression of APP gene itself has also been associated with AD pathogenesis. 
Genetic duplications of APP locus on chromosome 21(Rovelet-Lecrux, Hannequin et 
al. 2006), trisomy 21 seen in Down’s syndrome patients(Podlisny, Lee et al. 1987) are  
believed to cause AD pathology. In addition it has been shown that APP promoter 
polymorphism (Theuns, Brouwers et al. 2006) also causes increased APP expression 
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levels, resulting in increased Aβ42.Therefore it is important to elucidate the 
mechanisms that regulate APP expression to further understand the pathogenesis of 
the disease. 
       miRNAs , small non coding RNAs and novel regulators of gene expression, bind 
to 3’UTR of their target mRNAs leading to translational repression. Changes in 
miRNA expression or function might therefore contribute to various human diseases 
and thus makes them potential disease biomarkers(Chang and Mendell 2007). It has 
been shown that miRNAs are abundantly expressed in the central nervous system and 
most of the miRNAs show high degree of spatial and temporal specificity with 
important regulatory roles in synaptic plasticity, neuronal differentiation and 
specification (Barad, Meiri et al. 2004; Miska, Alvarez-Saavedra et al. 2004; 
Smirnova, Grafe et al. 2005). miRNAs have also been shown to be involved in 
various neurodegenerative disorders such as Parkinson’s disease wherein loss of miR-
133b is shown to play an important role in disease progression(Kim, Inoue et al. 
2007). In addition miRNAs are also associated with other neurodegenerative diseases 
such as miR-132, miR-124a and miR-9/9* down regulation resulting in predisposition 
to Huntington disease (Packer, Xing et al. 2008) and miR-200 is involved in HDAC 
deregulation in amylotropic lateral sclerosis (Scott, Mattie et al. 2006). Hence the 
hypothesis that miRNAs are important component of gene regulatory networks could 
potentially contribute to neurodegenerative disorders in humans is gaining popularity.  
         A number of studies have recently implicated dysregulation of miRNAs in 
Alzheimer’s disease with important AD associated genes demonstrated to be the 
targets. The hippocampus, an important part of the brain with memory functions is 
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the first region of the brain to be affected by the disease(Mann 1989). An initial study 
(Lukiw 2007) associating differential microRNA expression to AD, was the first such 
study to report the up regulation of miR-9, miR-125b and miR-128 in the 
hippocampus of AD affected brains. This study involved expression profiling of 13 
most abundant brain miRNAs was previously reported by (Sempere, Freemantle et al. 
2004). A second study by the same group (Lukiw and Pogue 2007) demonstrated that 
brain derived primary neural cells (HN cells) treated with metal salts that activate 
ROS also showed similar miRNA changes (increased expression of miR-9, miR-128 
and miR-125b) as seen in the AD brain samples. This suggests and supports the 
hypothesis that ROS influence AD brain through pathways specifically mediated by 
miRNAs. Moreover miR-125b which is higher in both HN cells and AD brains is a 
predicted regulator of syanpsin I and synapsin II and thus it can by hypothesized that 
down regulation of synapsins observed in AD may be therefore explained by the up 
regulation of miR-125b(Lukiw 2007; Lukiw and Pogue 2007). This study was then 
followed by two more miRNA expression profiling studies (Cogswell, Ward et al. 
2008; Hebert, Horre et al. 2008) that demonstrated differential miRNA regulation 
between AD and control brain samples. The noteworthy fact consistently reported in 
all the different studies on miRNA expression profiling was the up regulation of miR-
125b and the down regulation of miR-9 and miR-210. This is important because miR-
125b and miR-9 are key miRNAs with roles in brain development and function and 
are also involved in neurological diseases such as Downs Syndrome and Huntington’s 
disease (Krichevsky, King et al. 2003; Maes, Chertkow et al. 2009). miRNA 
dysregulation has not only been observed in  AD post-mortem brain samples but has 
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also been seen in CSF which might make miRNAs putative biomarkers not only for 
AD but also for other neurodegenerative diseases(Cogswell, Ward et al. 2008). 
However it still remains nuclear as to how changes in miRNA in neurons or brains 
correlate with changes in the CSF. But the fact the Tau and its changes in expression 
in AD can be measured in CSF suggests further investigations for miRNA expression 
changes that might be seen in the CSF. Of interest miR-146b is down regulated in 
CSF of AD patients whereas miR-138 is the only brain enriched miRNA that is up 
regulated (Cogswell, Ward et al. 2008). miR-146b regulates toll-like receptors in 
human monocytes(Taganov, Boldin et al. 2006), but its role in AD pathogenesis 
remains to be determined. However miR-146a also proposed to function in the 
control of toll-like receptor signaling(Taganov, Boldin et al. 2006), is up regulated in 
AD brains and in IL-1β, Aβ42 and/or oxidatively stressed HN cells, coupled with 
down regulation of complement factor H (CFH)(Lukiw, Zhao et al. 2008). It has been 
shown that up regulation of inflammatory gene expression due to over activation of 
NF-κB supports the development and progression of AD pathogenesis (Colangelo, 
Schurr et al. 2002). This study (Lukiw, Zhao et al. 2008) therefore provides evidence 
that miR-146a regulates complement factor H, a protein contributing to the brain’s 
immune and inflammatory response in AD. miR-138 which is up regulated in CSF of 
AD subjects, negatively regulates dendritic spine development in rat hippocampal 
neurons (Siegel, Obernosterer et al. 2009), but its role in AD pathogenesis still 
remains unknown.  
        Age being the greatest risk factor for Alzheimer’s Disease, it is possible that 
mechanisms that are involved in aging might also be under the regulation of miRNA 
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and this might also be one of the contributing factors to AD pathology. Some of the 
miRNAs identified by expression profiling studies have been linked to DNA damage 
responses in aging and therefore might be involved in neurodegenerative processes in 
the brain. Oxidative DNA damage has been shown to occur early in the 
pathophysiology of AD (Migliore, Fontana et al. 2005; Lovell and Markesbery 2007). 
miRNA changes have also been shown to correlate with the oxidative damage in AD 
patients. Results from studies on miRNA and gene expression in peripheral blood 
mononuclear cells from AD subjects demonstrate impaired DNA repair and 
antioxidant gene responses which correlate with up regulation of miR-181b, miR-
200a, miR-517* and miR-520h. Up regulation of these miRNAs may possibly impair 
DNA repair and oxidative stress response by repressing the expression of genes 
involved in these DNA repair processes (Schipper, Maes et al. 2007). AD tissues also 
undergo oxidative stress due to increased neural levels of redox oxidative species and 
transition metals (Schipper 2004). Such oxidative neural stress in AD brains has been 
shown to up regulate miR-9, miR-125b and miR-128. It could therefore be 
hypothesized that up regulation of these miRNA may be down-regulating the genes 
which might be protective against stress inducing agents in AD (Lukiw 2007; Lukiw 
and Pogue 2007). Expression profiling of miRNAs in AD subjects may thus serve as 
a means of determining miRNAs as putative diagnostic and prognostic biomarkers for 
predicting the onset of the disease.  
         Disorders in proteolytic processing of APP have been shown to result in AD 
pathogenesis with increased Aβ production due to increase in BACE1 and PSEN1 
levels. The dysregulation of BACE1 has been shown to play a major role in AD 
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pathogenesis (Dominguez, Hartmann et al. 2004; Guo and Hobbs 2006). BACE 1 is 
enriched in neurons but its gene expression is not very well understood (Rossner, 
Sastre et al. 2006). However recently it has been shown that BACE 1 is targeted by 
miRNA which regulate post transcriptional BACE1 expression. It was demonstrated 
that over-expression of miR-29a, -29b1 and miR-9 reduce BACE1 levels in Human 
Embryonic Kidney cells. The miR-29a/b1 cluster was also shown to be significantly 
down regulated in AD patients with abnormally high BACE1 levels in these patients 
(Hebert, Horre et al. 2008). Another miRNA, miR-107, was also shown to be 
decreased in AD subjects with increased BACE1 mRNA levels (Wang, Rajeev et al. 
2008). Similar reduction was seen for BACE1 in vitro, mediated by binding sites for 
miR-298 and miR-328 in BACE1 3’UTR(Boissonneault, Plante et al. 2009).  Hence it 
can be speculated that if by chance or as a function of aging, the miR-29a/29b1 
cluster or miR-107 are affected, this could lead to abnormal increase in BACE1 
expression due to its decreased suppression leading to Aβ production which could 
increase AD risk.  
      Even though APP cleavage plays a central role in Alzheimer’s disease pathology, 
observations made in Down’s syndrome patients have raised the possibility that 
excess or over-production of APP protein due to hyper-expression of APP, may 
contribute to AD risk by increasing Aβ production.  APP-like protein in C.elegans 
encoded by APPL gene is targeted by let-7 miRNA suggesting that let-7 can also be 
involved in APP gene regulation in humans (Niwa, Zhou et al. 2008), since 
microRNA let-7i has been reported to decrease in AD brain(Hebert, Horre et al. 
2008). We were the first to report that miR-106a which is down regulated in AD 
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brains (Hebert, Horre et al. 2008) reduces APP protein levels in Human embryonic 
kidney cells(Patel, Hoang et al. 2008). This initial study therefore validates the 
hypothesis that APP can be subject to post transcriptional regulation by microRNA. 
APP was then also shown to be down regulated by miR-20a, miR-17-5p and miR-
106b in cell lines in vitro(Hebert, Horre et al. 2008). This study also demonstrated 
developmental co-regulation of APP and miR-20a, miR-17-5p and miR-106b in 
differentiating neurons, in vitro, obtained from mouse brain at different 
developmental stages.  
        Studies in rat hippocampal neurons cultured in vitro identified miR-101 as a 
putative regulator of APP expression in these neurons. miR-101 over expression 
showed a reduction in Aβ accumulation and Cox-2 levels in these neuronal 
cultures(Vilardo, Barbato et al.). Increased levels of Cox-2 contribute to neuro -
inflammation in AD (Yasojima, Schwab et al. 1999). Reduction of these two 
pathological features by miR-101 suggests a protective role of this microRNA in 
Alzheimer’s disease. microRNA studies done on SAMP8 strains of mice, which have 
significantly increased APP levels in the hippocampus of aged mice,  identified miR-
16 as a transcriptional regulator of APP in these mice(Liu, Liu et al.).  
      As mentioned previously, expression profiling of post-mortem AD and control 
brains have demonstrated significant changes in miRNA expression patterns in 
different brain regions(Hebert and De Strooper 2009). The miRNAs identified in 
these samples also include miRNAs that regulate AD associated genes such as APP 
and BACE1. (Hebert, Horre et al. 2008; Hebert, Horre et al. 2008; Patel, Hoang et al. 
2008; Wang, Rajeev et al. 2008). However it is still not clear if the miRNA 
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dysregulation seen in AD patients is a cause or a consequence of the disease. It can 
therefore also be hypothesized that Aβ that accumulates in AD can be one of the 
causes of neuronal miRNA dysregulation contributing to AD pathology. A study done 
on mouse hippocampal neuronal culture demonstrated down-regulation of all tested 
miRNA in response to Aβ peptides. This deregulation was similar to the miRNA  
deregulation that was observed in the hippocampus of APP23 mice which show Aβ42 
deposits(Schonrock, Ke et al.). miR-9, 181c, 30c, 20b, and let-7i were more 
significantly down regulated in the hippocampus of these APP 23 mice in this study, 
all of which were also shown to be altered in AD brains(Nunez-Iglesias, Liu et al.). 
Therefore it can be suggested that down regulation of these miRNA can be at least in 
part due to the presence of Aβ. Thus Aβ can be an important regulator of miRNA 
expression which has a major effect of AD pathogenesis.  
       Aβ accumulation has been shown to result in neuronal loss. However neuronal 
degeneration has also been shown to coincide with hyper-phosphorylation of the 
endogenous microtubule associated protein tau. Under normal physiological 
conditions tau maintains the assembly of the microtubules in the neurons. Disruption 
of the normal phosphorylation  state of tau leads to the development of neurofibrillary 
tangles which are also observed, along with amyloid plaque deposits in AD brains 
(Ballatore, Lee et al. 2007). miRNAs have also been implicated in regulating tau 
metabolism and resulting toxicity. Suppression of miRNA maturation in Drosophila 
cells has been shown to enhance tau mediated toxicity(Bilen, Liu et al. 2006). miR-
128 has been shown to regulating tau degradation and aggregation in cultured cells by 
regulation BAG2 expression; a gene encoding a protein BAG2 involved in tau 
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degradation and clearance(Carrettiero, Hernandez et al. 2009). More recently is 
shown that miRNAs belonging to miR-15 family are regulators of ERK1, an enzyme 
responsible to maintaining normal phosphoryaltion state of tau in neurons. The study 
showed that loss of miRNA-15 function and or maturation leads to ERK1 over-
expressed in mouse neurons which could potentially result in tau hyper-
phosphorylation. miR-15  was also shown to be down regulated in AD brains, thereby 
providing strong evidence that miR-15 may contribute to tau hyper phosphoryation 
and the resulting pathology in Alzheimer’s disease(Hebert, Papadopoulou et al.).  
       Thus miRNAs which are important modulators of gene expression can be 
attractive therapeutic targets for Alzheimer’s disease. However the effect of miRNA 
in complex regulatory networks of Alzheimer’s disease is not yet known. Therefore it 
will be important to determine which miRNAs shown altered expression in different 
genetic backgrounds and different regions of the brain to further understand their 
regulatory role in the salient cause-effect relationships in various pathways and genes 
associated with Alzheimer’s disease.  
 
SUMMARY OF DISSERTATION RESEARCH: 
       miRNAs are important factors in gene regulation and are associated with various 
known human diseases. miRNAs have also been shown to be involved in 
neurodegeneration (Hebert and De Strooper 2007; Kim, Inoue et al. 2007) and their 
role in Alzheimer’s Disease is becoming more apparent. The first report(Lukiw 2007) 
showing the association of miRNA with Alzheimer’s disease demonstrated 
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differential miRNA expression between control and AD brains. This suggested some 
regulatory role of the miRNAs in AD pathogenesis.  
        A number of studies thereafter reported miRNA dysregulation AD and their 
association with obvious transcripts such as BACE1 which is the first enzyme in the 
APP proteolytic pathway responsible for Aβ formation. Studies demonstrated 
significant decrease is miR-107 and miR-29a/29b1 in AD patients with remarkable 
decrease in BACE1 transcript in these patients. In vitro studies also showed BACE 1 
regulation by these microRNAs(Hebert, Horre et al. 2008; Wang, Rajeev et al. 2008).   
    APP is central to Alzheimer’s disease pathology and another obvious target since it 
plays an important role in AD. APL-1 homolog of APP in C. elegans was shown to be 
developmentally regulated by let-7(Niwa, Zhou et al. 2008). APP mRNA is also 
predicted as a putative target with various miRNA target sites in its 3’UTR, most of 
which are not yet experimentally validated. Therefore, here we experimentally 
validate and investigate the role of miRNA in APP gene regulation. We work with an 
in vitro model using human cells to test the effect of miRNA on APP gene regulation. 
We also extend our studies to human embryonic neural progenitor cells to validate the 
results that we obtained from our human cell lines. Since Alzheimer’s disease is a 
neurodegenerative disorder we further extend our studies from human cell lines to 
primary neurons obtained from 129S1-R1.40 APP transgenic mice. These mice have 
the Yeast Artificial chromosome containing the entire 300kb human APP gene 
bearing the Swedish Mutation (KM670/671N) (Lehman, Kulnane et al. 2003).  
     To determine if APP mRNA is regulated by miRNA, we first located the putative 
miRNA target sites in the APP 3’UTR. We utilized miRBase and TargetScan which 
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are widely used miRNA database. Once we obtained an initial list of the miRNAs 
predicted to target APP, from this website, we used the BLAST program to compare 
the miRNA target sequence with the APP 3’UTR. Using BLAST we aligned the 
target sequences of the miRNAs, predicted to target APP, with the APP 3’UTR and 
located regions of similarity thereby identifying the putative miRNA target sites in 
the APP 3’UTR. But since Alzheimer’s disease is a brain restricted disease, it is 
important to identify miRNAs that regulate APP expression in the brain. We therefore 
performed a database and literature search to identify and determine which of the 
microRNAs from our initial list, predicted to target APP 3’UTR, are expressed in 
human brains. We therefore further narrowed down to only those predicted miRNAs 
from our list that might be involved in regulating APP gene expression in the human 
brain. We further validated the brain expression of these miRNA, by quantitative real 
time PCR, on RNA obtained from a 81 yr old non-AD Caucasian male.  
     Having identified a list of brain expressed miRNA we utilized a luciferase reporter 
gene expression system to confirm the predicted miRNA binding sites in the APP 
3’UTR. Using naïve human embryonic kidney (HEK) 293 cells, we monitored the 
effect of over-expressing miRNAs, predicted to target APP 3’UTR, by means of a 
luciferase signal by using the luciferase reporter vector bearing the APP 3’UTR with 
all the putative miRNA target sites. We showed for the first time that brain expressed 
hsa-miR-106a not only binds to its predicted target site in APP 3’UTR, but also 
decreases protein levels in these cells, with no effect on APP mRNA levels. This 
suggests a translational regulation of APP by this miRNA. We were therefore the first 
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people to demonstrate miRNA mediated regulation of APP gene expression in 
vitro(Patel, Hoang et al. 2008).  
      We then further investigated the role of other brain expressed miRNA on APP 
gene regulation in the above mentioned cell line. We observed that all the brain 
expressed miRNA bind to their putative target sites in APP 3’UTR and regulated 
reporter gene expression. Over-expression of these miRNA also leads to a significant 
decrease in APP protein levels, with all, except one miRNA miR-495, demonstrating 
no effect on APP mRNA levels. miR-495 showed a significant decrease in APP 
mRNA levels indicating that it might be involved in post transcription gene 
regulation, unlike translational regulation as seen other other miRNAs. We extended 
these findings to human neural progenitor stem cells (hNP). These cells are obtained 
as undifferentiated neural progenitor cells which can be differentiated into a human 
neuron population. Using QRT-PCR we determined the endogenous expression of 
our brain expressed miRNA in these hNP cells and using specific miRNA inhibitors 
we endogenously knocked-down these miRNAs in these undifferentiated hNPs. We 
observed that knockdown of our brain expressed microRNAs in these hNPs lead to a 
significant up regulation of luciferase gene expression indicating the loss of miRNA 
binding to their target sites in APP 3’UTR. Knockdown of these miRNAs also lead to 
a significant increase in APP protein levels further validating our initial results that 
we obtained on over expressing these miRNAs in our naïve HEK 293 cells line.  
        APP is a ubiquitously expressed protein with APP 695 isoform showing high 
expression in brain neurons. In the brain APP has been shown to be important in 
synaptic transmission, plasticity and memory. APP over expression in transgenic 
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mice had been reported to decrease dendritic spines resulting in cognitive decline in 
these transgenic mice (Lehman, Kulnane et al. 2003). We therefore extended our 
study from human cell lines to hippocampal neuronal cultures obtained from the 
129S1-R1.40 APP transgenic mice. Over-expressing our brain expressed microRNA 
in these neurons lead to a significant decrease in APP protein levels. Since these are 
brain expressed microRNAs we also show novel expression of these microRNAs in 
neurons and microglial in the hippocampus of a human brain using in situ 
hybridization. These results demonstrate and support our hypothesis that human APP 
levels can be regulated by microRNA, which might play an important role in AD 
pathogenesis.  
     Since miRNA play an important role in APP gene regulation as observed from our 
data, it can also be possible that disruption of miRNA mediated expression regulation 
might lead to increased APP levels and increased disease risk. To investigate this 
idea, we identified a genetic variant within the APP 3’UTR of probands from early 
onset familial Alzheimer’s disease families linked to the APP-region on chromosome 
21. This variant, rs45455403, is located in the putative miR-495 miRNA target site in 
the APP 3’UTR. This led us to hypothesize that this variant disrupts miR- 495 
mediated repression of APP expression. Our functional data demonstrates that the 
minor allele of rs45455403 disrupts miR-495 binding to its target sequence and 
significantly alters APP protein levels. Thus taken together, our results demonstrate 
that APP levels can be regulated by miRNAs in vitro and that rare genetic variants in 
APP 3’UTR can alter miRNA mediated regulation of APP gene thereby increasing 
APP levels and increasing AD risk.  
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   FIGURES: 
 
 
 
Figure 1-1 (Suzuki, Araki et al. 2006) : Maturation of APP during its transit to the 
plasma membrane from the Endoplasmic reticulum. 
 
 
 
 
 
 
 
 
Figure 1-2 (Suzuki, Araki et al. 2006) : Diagram showing three possible trafficking 
pathways of APP within neurites. In 1, APP is transported as full-length protein. In 2, 
CTFβ and sAPPβ are transported in separate vesicles. In 3, AICD, Aβ, and sAPPβ are 
transported in separate vesicles. AICD (or pAICD) may bind either to an anchoring 
protein (as shown in the diagram), or directly to membrane acidic phospholipids (not 
shown in the diagram). Only the β-secretase processing pathway is shown 
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Figure 1-3 (Suzuki, Araki et al. 2006) : Regulated Intramembrane Proteolysis of 
APP. APP undergoes proteolysis by α-, β-, and γ- secretases. α -secretase and β -
secretase produce non-plaque forming p3, while β -secretase and γ -secretase produce 
amyloid plaque-forming Aβ.  The different regions of the APP protein are indicated. 
 
 
 
 
 50
 
 
 
 
Figure 1-4 (Allinson, Parkin et al. 2003) Primary sites of cleavage by -, ,- and -
secretases. The grey box indicates the A  peptide within APP. Enlargement of the A
 peptide region shows amino acid sequence in single-letter code and primary sites of 
cleavage by -, ,- and -secretases. The A  peptide is numbered from Asp1, with -
secretase cleaving between Lys16 and Leu17. 
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Figure1-5 (Wolfe 2006) Components and assembly of the γ-secretase complex. 
(A) γ-Secretase is composed of four different integral membrane proteins:  presenilin, 
nicastrin, Aph-1, and Pen-2. Presenilin undergoes endoproteolysis into an N-terminal 
fragment (NTF) and a C-terminal fragment (CTF) that remain associated. Two 
conserved aspartates within adjacent transmembrane domains are essential for both 
presenilin endoproteolysis and γ-secretase activity. (B) Model for how the 
components of γ-secretase are arranged within the active protease complex 
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Figure (1-6)(Chen 2005) MicroRNA Biogenesis                                                             
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Figure (1-7) (Filipowicz 2008) Possible mechanisms of the microRNA-mediated 
post-transcriptional gene repression in animal cells 
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ABSTRACT: 
A number of studies have shown that increased APP levels, resulting from either a 
genomic locus duplication or alteration in APP regulatory sequences, can lead to 
development of early-onset dementias, including Alzheimer’s disease (AD). 
Therefore, understanding how APP levels are regulated could provide valuable 
insight into the genetic basis of AD and illuminate novel therapeutic avenues for AD. 
Here we test the hypothesis that APP protein levels can be regulated by miRNAs, 
evolutionarily conserved small noncoding RNA molecules that play an important role 
in regulating gene expression. Utilizing human cell lines, we demonstrate that 
miRNAs hsa-miR-106a and hsa-miR-520c bind to their predicted target sequences in 
the APP 3’UTR and negatively regulate reporter gene expression. Over-expression of 
these miRNAs, but not control miRNAs, results in translational repression of APP 
mRNA and significantly reduces APP protein levels. These results are the first to 
demonstrate that levels of human APP can be regulated by miRNAs. 
 
 
Key words: Untranslated region, HEK-293, hsa-miR-106a, hsa-miR-520c 
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INTRODUCTION: 
Accumulating evidence suggests that increased expression of the amyloid 
precursor protein gene (APP) increases Alzheimer’s disease (AD) risk. The resulting 
increase in APP protein levels results in increased Aβ levels, leading to synaptic 
dysfunction, neurodegeneration and, eventually, cognitive decline in the brains of AD 
patients. 
          APP levels can be regulated at the genomic, transcriptional or translational 
level. At the genomic level, Down’s Syndrome (Trisomy 21) patients have three 
copies of the APP gene and develop AD symptoms early in life (Rumble, Retallack et 
al. 1989). Similarly, duplication of the APP locus, in the absence of a full trisomy 21, 
also leads to early-onset AD (Sleegers, Brouwers et al. 2006).  Dysregulation of APP 
transcription can also increase the risk of AD. Genetic variants in the APP promoter 
increase APP transcription by ~ 2-3 fold and have been reported to increase AD risk 
(Brouwers, Sleegers et al. 2006).  Growth factors have been reported to control APP 
mRNA half-life (Rajagopalan and Malter 2000). These growth factors effects are 
dependent on a 29 bp sequence in the APP 3’ UTR (Rajagopalan, Westmark et al. 
1998; Rajagopalan and Malter 2000). APP translation is also regulated; for example, 
IL-1 can induce an increase in APP translation (Rogers, Leiter et al. 1999). IL-1 is a 
pro-inflammatory cytokine and genetic variants have been linked to increased AD 
risk (Griffin, Nicoll et al. 2000),(Bertram, McQueen et al. 2007). Taken together, 
these findings provide strong evidence that increased APP levels increase AD risk.  
MicroRNAs (miRNAs) are small noncoding RNAs that control gene 
expression post-transcriptionally. Complementary binding between miRNAs and 
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sequences within the 3’ UTR of target genes results in repression of target gene 
expression by translational inhibition or mRNA degradation (Pillai 2005). 
Approximately 700 miRNA genes are encoded in the human genome and recent 
evidence demonstrates that some miRNAs are differentially expressed in AD patients 
compared to age-matched controls (Lukiw 2007). These differences in miRNA 
expression may play an important role in AD pathogenesis. In an attempt to address 
this possibility, we test the hypothesis that miRNAs can regulate APP levels.  
      Bioinformatics’ analysis predicts that the 3’ UTR of human APP contains 28 
unique miRNA target sites(John, Enright et al. 2004). To experimentally confirm that 
APP levels can be regulated by miRNAs, we chose to initially study miRNA hsa-
miR-106a (miR-106a; Figure 2-1) since (i) the putative target site in the APP 3’UTR 
is 100% complementary to the seed region of the miRNA, (ii) it has a large free 
energy of seed region binding, and (iii) it is expressed in human brain(Liang, Ridzon 
et al. 2007). 
     Here we show for the first time that APP expression can be regulated by 
microRNA. Using human cells lines we demonstrate that hsa-miR-106a and miR-
520c bind to their predicted target sequences in APP 3’UTR and regulate gene 
expression. We also show that these miRNAs significantly reduce APP protein levels 
in vitro in our cells lines, without any effect on APP mRNA levels. Therefore our 
results suggest that miR-106a and miR-520c may be involved in translational 
regulation of APP gene expression.  
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MATERIALS AND METHODS: 
 
Reporter Vectors and DNA constructs. 
Reporter vectors containing the putative miRNA target sites from the APP 3’UTR, 
were synthesized with double-stranded oligos perfectly complementary to putative 
miRNA target sites and oligos in which the seed regions were mutated. The miR-106a 
target oligos had the sequence (seed region underlined):   
 5’  CTAGTAATCCCTGTTCATTGTAAGCACTTTTGCTCAGCA 3’  
3’             ATTAGGGACAAGTAACATTCGTGAAAACGAGTCGTTCGA 5’ 
The mutant miR-106a target oligos had nucleotides three through six of the seed 
region mutated (italicized): 
5’   CTAGTAATCCCTGTTCATTGTAAGCGTCCTTGCTCAGCA 3’ 
3’            ATTAGGGACAAGTAACATTCGCAGGAACGAGTCGTTCGA 5’ 
We utilized established methods (Cheng, Byrom et al. 2005) to clone these synthetic 
versions of putative miRNA target sites into a luciferase reporter gene (pMIR-
REPORT; Ambion).  
 
Cells and Cell Culture. 
Naïve human embryonic kidney (HEK)-293 cells were purchased from ATCC. Cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum, 2 mM L-glutamine,100 units/ml penicillin and 100 g/ml 
streptomycin.  
 
 59
 
Transfections and Luciferase Assays. 
10,000 Naïve HEK-293 were plated in 24 well plates. The next day, cells were 
transfected with a miRNA over expression vector (Huang, Gumireddy et al. 2008), 
reporter vectors bearing either the miRNA target sequence or the miRNA seed region 
mutant target sequence, and one tenth of the molar volume of pRL-SV40, a Renilla 
Luciferase control vector.  We utilized Arrest-in transfection reagent (Open 
Biosystems Inc.); any differences in transfection efficiency were accounted for by 
measuring Renilla luciferase activity. 48 hours post- transfection, cell were lysed 
using 100L of GLB (Glo Lysis Buffer, Promega). Firefly and Renilla luciferase 
activities were measured using a dual luciferase reporter assay kit (Promega), per the 
manufacturer’s protocol. Firefly luciferase activity was normalized to Renilla 
luciferase activity. 
 
Western Blot Analysis. 
200,000 Naïve 293 cells were plated in 6 well plates. The next day, 
cells were transfected with a miRNA over expression vector. 48 hours post 
transfection. Cells were lysed in RIPA cell lysis buffer (50 mM Tris-HCL pH 7.4, 
150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM PMSF and 1 μg/ml aprotinin, 1 
μg/ml leupeptin, and 1 μg/ml pepstatin), and centrifuged at 14,000 rpm for 15 
minutes at 4°C. The resulting supernatant was transferred to a new micro-centrifuge 
tube. The protein concentration of the cell lysates was determined using the BCA 
protein assay kit (Pierce, Rockford, IL) according to the manufacturer's instructions. 
 60
Equal quantities of protein were loaded into the wells of 4–12% Bis-Tris 
polyacrylamide gels (Invitrogen) along with See Blue plus 2 protein marker 
(Invitrogen). Gels were run using MES running buffer and transferred to PVDF 
membrane (Immobilon PSQ, Millipore) using a semi-dry transfer apparatus (Owl 
Scientific) and NuPage transfer buffer (Invitrogen). PVDF membranes were blocked 
in TBST with 5% dry milk for at least two hours, washed extensively, then incubated 
with primary antibody for either one hour at room temperature or overnight at 4°C. 
After removing the primary antibody, membranes were extensively washed and 
incubated with either goat-anti-rabbit-HRP or goat-anti-mouse-HRP secondary 
antibodies (1:10,000; GE) for one hour at room temperature. Membranes were 
washed and developed using West Dura Extended Duration Substrate (Pierce). The 
blot was visualized using a FluoroChem 8900 imaging system (Alpha Innotech), and 
signals were quantified using AlphaEase Fc software. To account for any differences 
in loading, target band densitometries were divided by actin densitometries obtained 
from the same lane. These corrected densitometries were normalized to controls in 
each experiment. 
 
Antibodies. 
A polyclonal antibody specific for the C-terminus of human APP (A8717; Sigma 
Aldrich, Inc) and a monoclonal antibody specific for human β-Actin (A5441; Sigma 
Aldrich) were used as primary antibodies. Secondary antibodies were HRP-
conjugated goat anti-rabbit (GE Healthcare) and HRP-conjugated goat anti-mouse 
(GE Healthcare). 
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RNA extraction and Quantitative PCR. 
48 hours post-transfection, cells were washed with cold PBS and total RNA was 
isolated using RNeasy Mini Kit (Qiagen Inc.). To quantify APP mRNA levels, cDNA 
was synthesized using total RNA, N6 random primers and SuperScript II Reverse 
Transcriptase (Invitrogen). cDNA was then diluted 1:15 using RNase free water and 
mixed with APP or GAPDH primer/probe sets (Applied Biosystems, Inc.; APP 
Catalog # Hs00169098_m1; GAPDH Catalog # Hs99999905_m1), 2X PCR 
Universal Master Mix (Applied Biosystems, Inc.) and amplified using an ABI 7500 
Real Time PCR system following the manufacturer’s directions. GAPDH was used as 
an internal control. To determine differences in APP mRNA levels, we utilized the 
ΔΔCt method.  
To quantify miRNA levels, cDNA was reverse transcribed from total RNA 
samples using specific miRNA primers from the TaqMan MicroRNA Assays and 
reagents from the Taq Man MicroRNA Reverse Transcription kit (Applied 
Biosystems). The resulting cDNA was amplified by PCR using TaqMan MicroRNA 
Assay primers with the TaqMan Universal PCR Master Mix and analyzed with a 7500 
ABI PRISM Sequence Detector System according to the manufacturer's instructions 
(Applied Biosystems). The relative levels of miRNA expression were calculated from 
the relevant signals by the ΔΔCt method by normalization to the signal of RNU44 
(Nikiforova, Tseng et al. 2008).  
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Statistical Analysis. 
Values in the text and figures are presented as means ± standard deviations of 
experiments carried out in triplicate, at least. Each experiment was carried three 
times. Equal variance or separate variance two-sample student’s t-test were used, as 
appropriate, to compare two groups. Where appropriate, Bonferroni analysis was used 
to correct for multiple comparisons within a single experiment. 
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RESULTS: 
miR-106a target site in APP 3’UTR regulates reporter gene expression: To 
determine if the putative miR-106a target site in the APP 3’UTR is capable of 
regulating gene expression, we cloned it into the 3’ UTR of firefly luciferase. We co-
transfected this reporter into naïve HEK-293 cells along with a miR-106a over-
expression vector (Huang, Gumireddy et al. 2008) and measured luciferase activity 
(Figure 2-2). We observed a significant ~50% decrease (p<0.0001) in luciferase 
activity when the putative miR-106a target site was included in the reporter compared 
to either a reporter lacking the putative target site or reporter carrying a seed-region 
mutant of the putative miR-106a target site. To determine if this effect was simply 
due to over-expressing miRNAs, we repeated the experiment while over-expressing 
miR-373, a miRNA not predicted to target the APP 3’UTR. We observed no change 
in luciferase activity. Another miRNA, miR-520c, shares the same seed region target 
sequence as miR-106a but is not expressed in human brain (Liang, Ridzon et al. 
2007). Therefore we tested miR-520c, we observed that miR-520c over-expression 
significantly decreased luciferase activity when the putative miR-106a target site was 
included in the reporter compared to either a reporter lacking the putative target site 
or a reporter carrying a seed-region mutant of the putative miR-106a target site.  
    To confirm that the miRNAs were being over-expressed, we utilized RT-QPCR to 
quantify miRNA levels and observed significant increases in both miR106a and miR-
520c (Table 2-1) levels (p<0.0001).   
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Over expression of miR-106a and miR-520c reduce APP levels in vitro: Having 
demonstrated that over-expression of miR-106a or miR-520c was capable of 
repressing reporter gene expression via interaction with its putative target site, we 
investigated whether over-expression of these miRNAs could decrease endogenous 
APP levels in human cell lines. We transfected naïve HEK-293 with miR-106a and 
miR-125b over-expression vectors and then performed quantitative western blot 
analysis to determine APP steady state levels. We utilized miR-125b as a negative 
control since it is not predicted to target APP but has increased expression in AD 
brain (Lukiw 2007). We observed that miR-106a over-expression significantly 
decreased APP levels (Figure 2-3A). Both APP isoforms expressed in this cell line, 
APP770 and APP751, were significantly and similarly affected. miR-106a over-
expression reduced APP levels by ~50% (p<0.01) compared to cells transfected with 
the empty vector (Figure 2-2B). Over-expression of miR-125b had no significant 
effect on APP levels. Over-expression of miR-520c had a similar effect on APP levels 
as miR-106a (Figure 2- 2C and 2D). 
 
microRNA over expression has no effect on APP mRNA levels: Most human 
miRNAs repress gene expression by inhibiting translation and do not affect target 
gene mRNA levels(Carthew 2006; Chendrimada, Finn et al. 2007). This seems to be 
the case in our experimental setting. We utilized RT-QPCR to determine if miRNA 
over-expression resulted in decreased APP mRNA levels. Over-expression of mir-
106a or mir-520c had no effect on APP mRNA levels (Figure 2-3).  Mir-106a and 
mir-520c, therefore, appear to inhibit translation of the APP transcript 
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DISCUSSION: 
Our results are the first to experimentally demonstrate that human APP levels 
can be regulated by miRNAs. In 2004, it was predicted that APP levels could be 
regulated by miRNAs(John, Enright et al. 2004); recently it was shown that 
expression of the C. elegans orthologue of APP, APL-1, is regulated by 
developmentally-timed miRNAs (Niwa, Zhou et al. 2008).   
In human neurons the APP 695 isoform is the predominant expressed isoform. 
All APP isoforms (695, 751, and 770) share the same 3’ UTR(Westmark, Shin et al. 
2006) therefore we expect that the mir-106a mediated regulation of APP levels that 
we observe in the HEK-293 cell line should also occur in neurons given that mir-106a 
is expressed in the brain. We do not expect mir-520c mediated APP regulation to 
occur since this miRNA is not expressed in brain. It is important to test miRNA 
regulation is a normal aspect of APP metabolism in neurons. If so, it will be 
important to determine whether AD pathogenesis is affected by alterations in miRNA 
function and/or expression. It is possible that aging- or environment-induced changes 
in miRNA expression, and/or sequence variation in miRNAs or their targets, 
contribute to increased APP levels and increased AD risk. Recently, it was 
demonstrated that expression of the -secretase BACE can be regulated by miR-
29a/b-1 and mir-107; furthermore, increased BACE levels correlated with decreased 
miR-29a/b-1 and mir-107 levels in AD patients (Hebert, Horre et al. 2008; Wang, 
Rajeev et al. 2008).  
Regardless of the biological roles of miRNA in APP metabolism, therapeutics 
based on miRNA-induced decrease in APP levels would offer a treatment targeting 
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the underlying pathophysiology of the disease. In the near future, substantial progress 
will be made in understanding the role of miRNAs in AD pathogenesis and in 
therapeutic approaches to treating AD.  
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FIGURE LEGENDS:  
 
Figure 2-1: Predicted mir-106a and mir-520c target sites in the 3’UTR of APP.  
 
Figure 2-2:  miR-106a target site in APP 3’UTR regulates reporter gene expression  
Over-expression of mir-106a or mir-520c, significantly reduced luciferase expression 
(p=0.0006) controlled by the putative mir-106a APP 3’UTR target sequence. This 
reduction is not observed when a seed region mutant of mir-106a (106a*) is utilized. 
miR-373 over expression has no effects on luciferase expression.  
 
Figure 2-3: Over expression of miR-106a and miR-520c reduce APP levels in vitro. 
(A) APP770 and APP751 levels are reduced in cells over-expressing mir-106a 
compared to cells expressing either mir-125b or the empty vector. (B) Quantification 
of these western blot results reveals that mir-106a over-expression significantly 
decreases APP levels (p<0.01) compared to cells expressing mir-125b or cells 
transfected with the empty vector. (C) APP770 and APP751 levels are reduced in cells 
over-expressing mir-520c compared to cells expressing the empty vector. (D) 
Quantification of these western blot results reveals that mir-520c over-expression 
significantly decreases APP levels (p<0.01) compared to cells transfected with the 
empty vector. 
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Figure 2-3: microRNA over expression has no effect on APP mRNA levels. QPCR 
results show that APP mRNA levels are not altered by mir-106a or mir-520c over-
expression. 
 
Table 2-1: Fold increase in miRNA levels. QPCR results significant increases in  
mir-106a and mir-520c levels due to over-expression. 
 
       For all experiments, three independent trials were performed. Error bars represent 
standard deviation. *p < 0.05; **p < 0.01, compared to the appropriate control. 
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FIGURES: 
Figure 2-1 miR-106a binding to its putative target site in APP 3’UTR 
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Figure 2-2 miR-106a target site in APP 3’UTR regulates reporter gene expression. 
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Figure 2-3A Over expression of miR-106a decreases APP protein levels 
                     
 
 
Figure 2-3B Quantification of above Western Blot 
 
 
 
 
 72
 
Figure 2-3C Over expression of miR-520c decreases APP protein levels 
 
            
 
Figure 2-3D Quantification of above Western Blot 
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Figure 2-4 miRNA over expression has no effects on APP mRNA levels 
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TABLES: 
 
Table 2-1 Relative change in microRNA levels 
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ABSTRACT: 
Alzheimer’s disease is a neurodegenerative disorder characterized by excessive 
accumulation of Aβ peptides in the brain. APP protein is ubiquitously expressed with 
APP695 isoform showing high expression in human neurons. APP over expression has 
been implicated in Alzheimer’s disease. microRNAs are important non coding RNAs 
that function in gene regulatory pathways and negatively regulate gene expression. 
Human brain has a distinct population of microRNAs that regulate brain gene 
expression functions. Reports have indicated that changes in microRNA expression 
patterns in the brain contribute to neurodegenerative diseases such as Alzheimer’s 
disease. APP has been predicted as a putative microRNA target and therefore we 
investigate whether brain expressed miRNAs participate in APP gene regulation. 
Here we show that brain expressed miRNAs not only regulate APP expression in 
vitro, but also endogenously in human neural progenitors cells. We also show brain 
expressed microRNA mediated regulation of APP gene expression in primary 
neurons from APP transgenic mice. In situ hybridization using human brain tissue 
sections demonstrated that miR-324-5p and miR-17-5p show neuronal expression and 
glial in the brain. We thus identify putative brain expressed miRNAs which function 
as endogenous regulators of APP expression, thereby suggesting that changes in brain 
expression of these miRNAs could lead to dysregulation of APP expression, 
increasing AD risk. 
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INTRODUCTION:  
       Accumulations of amyloid beta plaques, resulting from APP proteolysis by β- 
and γ-secretases are a characteristic feature of Alzheimer’s disease (Haass and De 
Strooper 1999; Vassar 2004). APP gene encoding the APP protein contains 19 exons 
which produce different alternatively spliced isoforms. All the isoforms of APP are 
ubiquitously expressed, but APP695 is produced primarily in the neurons and is the 
primary source of APP in the brain. APP 770 and APP 751 are present in intermediate or 
high levels in the brain, mostly in glial cells (Rockenstein, McConlogue et al. 1995). 
All these three isoforms however share the same 3’UTR (Westmark, Shin et al. 
2006). 
       Evidence suggests that increased expression of APP is associated with AD 
pathogenesis. This increased expression of APP has been reported to occur in Down’s 
syndrome patients, which is the cause of large incidence of AD in these 
patients(Podlisny, Lee et al. 1987). In the absence of trisomy 21, APP over expression 
is reported to occur due to genomic duplication of the APP locus on chromosome 
21(Rovelet-Lecrux, Hannequin et al. 2006). Reports also show increased APP protein 
levels due polymorphisms in the APP promoter that increase transcription(Theuns 
and Van Broeckhoven 2000) and certain growth factors and cytokines that increase 
APP translation(Rogers, Leiter et al. 1999). This therefore suggests that regulation of 
APP expression is important for the pathogenesis of Alzheimer’s disease.  
      Non-coding microRNAs have been shown to negatively regulate gene expression 
at post transcriptional levels(Bartel 2004) by imperfect base paring to the 3’UTR of 
their target genes(Brennecke, Stark et al. 2005). microRNAs are abundantly 
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expressed in the central nervous systems, where they have been shown to play an 
important role in synaptic plasticity, differentiation and neuronal cell 
specification(Kosik 2006; Schratt, Tuebing et al. 2006; Wulczyn, Smirnova et al. 
2007).  
      Since microRNAs are highly expressed in the brain, it can be hypothesized that 
changes in miRNA expression can contribute to neurodegenerative disorders like 
Alzheimer’s disease. microRNAs have been shown to play an important role in the 
development of sporadic Parkinson’s disease(Kim, Inoue et al. 2007). Expression 
profiling studies have shown altered miRNA regulation between AD brains and age 
matched controls (Nunez-Iglesias, Liu et al. ; Lukiw 2007). Also current reports have 
shown that microRNA are involved in Alzheimer’s Disease pathology by contributing 
to increase BACE1 expression in sporadic AD(Hebert, Horre et al. 2008; Wang, 
Rajeev et al. 2008). miR-20 family microRNAs have been shown to regulate APP 
levels during brain development(Hebert, Horre et al. 2008). Our previous report has 
shown in vitro regulation of APP expression by brain expressed miR-106a (Patel, 
Hoang et al. 2008). Here we extend our findings to other brain expressed miRNAs 
and show that these miRNAs can regulate APP expression in vitro, and at endogenous 
levels in human neural progenitor cells. Utilizing primary neurons from R1.40 APP 
transgenic mice, we demonstrate that over expression of these human brain expressed 
miRNAs results is translational repression of APP expression in these neurons. 
     Although in vitro miRNA expression analysis can provide important data, 
previous work has demonstrated that understanding the cellular level expression 
pattern for these microRNAs is important for brain microRNA studies (Nelson, 
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Baldwin et al. 2006). Neurodegenerative diseases usually affect distant cell 
populations in the brain. Therefore in situ hybridization (ISH) is useful in locating 
specific microRNA patterns in different cell types like neurons, astrocytes, microglia, 
oligodendrocytes and brain vasculature. Thus knowing which microRNAs are 
expressed in which cell types facilitates the identification of microRNA regulated 
disease relevant genes. It is known that APP695 had neuron specific expression 
(Rockenstein, McConlogue et al. 1995). Therefore using this technique we identified 
cell type specific expression of our microRNAs of interest, which as demonstrated by 
our in vitro system, regulate APP expression in our cell lines and primary transgenic 
mouse neurons. 
      We therefore experimentally validate that brain expressed miRNAs regulate APP 
gene expression, thereby suggesting that any alterations of miRNA expression for 
these microRNAs in the brain could contribute to changes in APP expression thereby 
increasing the risk of Alzheimer’s disease.  
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MATERIALS AND METHODS :  
 
 
Reporter Vectors and DNA constructs. 
The 3’UTR of APP (~1.2kb) was amplified from pGALA- luciferase vector with both 
APP 3’UTR and APP 5’UTR sequences (Rogers, Randall et al. 2002) and cloned into 
pMIR-REPORT luciferase vector (Ambion). Insertion of the UTR was confirmed by 
sequencing. The seed sequences in the target site of all different brain expressed 
miRNA in the APP 3’UTR luciferase vector were mutated using the QuickChange 
Site Directed Mutagenesis kit (Stratagene) according to the manufacturer’s 
instructions. 
 
Cells and Cell Culture. 
Naïve human embryonic kidney (HEK)-293 cells were purchased from ATCC. Cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum, 2 mM L-glutamine,100 units/ml penicillin and 100 g/ml 
streptomycin. STEMEZTM hNP1™ Human Neural Progenitor cells were purchased 
from Aruna Biomedical. Cells were cultured in AB2TM Neural medium supplemented 
with ANSTM supplement, 50μg/ml bFGF, 200mM L-Glutamine and 100 units/ml 
penicillin and 100 g/ml streptomycin.  Primary cultures for cortical and 
hippocampal neurons were prepared from embryonic day 18 R1.40 APP transgenic 
mice. Neurons were grown in neurobasal medium with B-27 supplement, L-
glutamine, and penicillin-streptomycin.  
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Transfections and Luciferase Assays. 
10,000 Naïve HEK-293 were plated in 24 well plates. The next day, cells were 
transfected with a miRNA over expression vector (Huang, Gumireddy et al. 2008), 
reporter vectors bearing either the wild type APP 3’UTR with miRNA target 
sequences or the mutant APP 3’UTR with the different miRNA seed region mutant 
target sequences, and one tenth of the molar volume of pRL-SV40, a Renilla 
Luciferase control vector.  We utilized Arrest-in transfection reagent (Open 
Biosystems Inc.); any differences in transfection efficiency were accounted for by 
measuring Renilla luciferase activity. 48 hours post- transfection, cell were lysed 
using 100L of GLB (Glo Lysis Buffer, Promega). Firefly and Renilla luciferase 
activities were measured using a dual luciferase reporter assay kit (Promega), per the 
manufacturer’s protocol. Firefly luciferase activity was normalized to Renilla 
luciferase activity. 
 
MicroRNA inhibition:  
STEMEZTM hNP1™ Human Neural Progenitor cells were plated in 96 well plates. 
The next day, cells were transfected with, 0.05 μg reporter vectors bearing the APP 
3’UTR with all the putative miRNA target sequences, 50nM final concentration of 
Anti-miR-miRNA inhibitors (Ambion) for the endogenously expressed miRNA in 
these cells, from our list of brain expressed miRNAs or FAM™-labeled Anti-miR™ 
Negative Control (Cat#AM17012, Ambion), and one tenth of the molar volume of 
pRL-SV40, a Renilla Luciferase control vector. We utilized Lipofectamine 2000 
 82
reagent (Invitrogen); any differences in transfection efficiency were accounted for by 
measuring Renilla luciferase activity. 24 hours post-transfection, cells were lysed 
using 100 μL of GLB (Glo Lysis Buffer, Promega). Firefly and Renilla luciferase 
activities were measured using a dual luciferase reporter assay kit (Promega), per the 
manufacturer's protocol. Firefly luciferase activity was normalized to Renilla 
luciferase activity. 
 
Western Blot Analysis. 
200,000 Naïve 293 cells and primary cortical and hippocampal were plated in 6 well 
plates. STEMEZTM hNP1™ Human Neural Progenitor cells were plated in 12 well 
plates The next day, Naïve 293 cells and primary neuronal cultures were transfected 
with a miRNA over expression vector. STEMEZTM hNP1™ Human Neural 
Progenitor cells were transfected with 50nM of the Anti-miR microRNA inhibitors. 
48 hours post transfection, cells were lysed in RIPA cell lysis buffer (50 mM Tris-
HCL pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM PMSF and 1 μg/ml 
aprotinin, 1 μg/ml leupeptin, and 1 μg/ml pepstatin), and centrifuged at 14,000 rpm 
for 15 minutes at 4°C. The resulting supernatant was transferred to a new micro-
centrifuge tube. The protein concentration of the cell lysates was determined using 
the BCA protein assay kit (Pierce, Rockford, IL) according to the manufacturer's 
instructions. Equal quantities of protein were loaded into the wells of 4–12% Bis-Tris 
polyacrylamide gels (Invitrogen) along with Odyssey Protein Molecular Weight 
Markers (Licor Biosciences). Gels were run using MES running buffer and 
transferred to PVDF membrane (Immobilon PSQ, Millipore) using a semi-dry transfer 
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apparatus (Owl Scientific) and NuPage transfer buffer (Invitrogen). PVDF 
membranes were blocked in Odyssey Blocking Buffer (Licor Biosciences) for at least 
two hours, washed extensively in 1X PBS with 0.1% Tween, then incubated with 
primary antibody for either one hour at room temperature or overnight at 4°C. After 
removing the primary antibody, membranes were extensively washed and incubated 
with goat-anti-rabbit-IRDye or goat-anti-mouse-IRDye secondary antibodies 
(1:10,000; Licor Biosciences) for one hour at room temperature. Membranes were 
washed with 1X PBS without Tween and the blot was visualized using a Licor 
Odyssey Infrared imaging system (Licor Biosciences), and signals were quantified 
using the Odyssey software. To account for any differences in loading, target band 
densitometries were divided by actin densitometries obtained from the same lane. 
These corrected densitometries were normalized to controls in each experiment. 
 
Antibodies. 
A polyclonal antibody specific for the C-terminus of human APP (A8717; Sigma 
Aldrich, Inc) and a monoclonal antibody specific for human β-Actin (A5441; Sigma 
Aldrich) were used as primary antibodies. Secondary antibodies were IRDye goat 
anti-rabbit (Licor Biosciences) and IRDye- goat anti-mouse (Licor Biosciences). 
 
RNA extraction and Quantitative PCR. 
48 hours post-transfection, cells were washed with cold PBS and total RNA was 
isolated using RNeasy Mini Kit (Qiagen Inc.). To quantify APP mRNA levels, cDNA 
was synthesized using total RNA, N6 random primers and SuperScript II Reverse 
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Transcriptase (Invitrogen). cDNA was then diluted 1:15 using RNase free water and 
mixed with APP or GAPDH primer/probe sets (Applied Biosystems, Inc.; APP 
Catalog # Hs00169098_m1; GAPDH Catalog # Hs99999905_m1), 2X PCR 
Universal Master Mix (Applied Biosystems, Inc.) and amplified using an ABI 7500 
Real Time PCR system following the manufacturer’s directions. GAPDH was used as 
an internal control. To determine differences in APP mRNA levels, we utilized the 
ΔΔCt method.  
To quantify miRNA levels, cDNA was reverse transcribed from total RNA 
samples using specific miRNA primers from the TaqMan MicroRNA Assays and 
reagents from the Taq Man MicroRNA Reverse Transcription kit (Applied 
Biosystems). The resulting cDNA was amplified by PCR using TaqMan MicroRNA 
Assay primers with the TaqMan Universal PCR Master Mix and analyzed with a 7500 
ABI PRISM Sequence Detector System according to the manufacturer's instructions 
(Applied Biosystems). The relative levels of miRNA expression were calculated from 
the relevant signals by the ΔΔCt method by normalization to the signal of RNU44 
(Nikiforova, Tseng et al. 2008).  
 
In Situ Hybridization: 
 Brain tissue was obtained from University of Kentucky ADC Brain bank. Brain 
sections used in this study were from Brain’s with a post mortem interval (PMI) of 
under 5 hours. Brain sections from two individuals; one without ante mortem 
cognitive decline (Non-Demented) and one demented individual with confirmed post 
mortem AD diagnosis. Post Mortem human brain sample was obtained via autopsy 
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within 5 hours of death. Tissues were fixed in 4% paraformaldehyde overnight at 4oC 
and then immersed in 20% sucrose again at 4oC for an additional 24 -48 hours. Tissue 
was cut to 25 microns on a freezing microtome and mounted onto pre-marked 
Superfrost® Plus slides. Cut tissue sections were allowed to air dry for 30 minutes.  
For in-situ hybridization  sections were first allowed to equilibrate to room 
temperature and then treated with Proteinase K (Roche; 40 µg/ml) for 20 min at room 
temperature, followed by quenching with glycine (Fisher Scientific; 1 mg/ml for 15 
min). After PBS washes, slides were   immersed in 10% formaldehyde (Fisher 
Scientific; 10 min), washed again twice in PBS, and treated with acetic 
anhydride/triethanolamine  (Fisher Scientific) for 10 min at room temperature. 
Sections were then washed in PBS (four times, 10 min each) followed by 5x SSC 
(twice, 5 min each). Pre hybridization was performed for 3 h at 37°C in a buffer 
prepared thus: 650 ml of ultrapure formamide [EMD (Omnipur), Gibbstown, NJ]; 250 
ml of 20x SSC; 1 ml of Tween 20; and 100 µg/ml purified yeast RNA 
(Roche). microRNA LNA probes (Exiqon) were diluted to 1.6 
µM in prehybridization buffer. For all the microRNA probes, hybridization was 
performed at 37°C. After overnight hybridization, which was performed with 
mechanical agitation, slides were washed at 37°C (twice with 5x SSC for 5 min, 
and then three times with 2x SSC in 50% formamide for 20 min each), followed by 
three washes in PBS with 0.1% Triton X-100 (PBST) at room temperature. 
Nonspecific antigen blocking was performed at 4°C in PBST with 2% sheep serum 
(Jackson ImmunoResearch, West Grove, PA) and 2 mg/ml RNase-free BSA (EMD 
(Omnipur)) for 2 h, followed by the addition of 1:1000 diluted AP-conjugated anti-
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digoxigenin antibody (Roche) and incubation overnight at 4°C. The next day, tissue 
was washed in PBST (four times 10 min each), and then in staining solution (10 
mM Tris-HCl, pH 9, 50 mM MgCl2, 100 mM NaCl, 0.1% Tween 20) twice for 5 min. 
Nitroblue tetrazolium and bromochloroindoyl phosphate (Roche) at 50 mg/ml each 
were added, and the staining reaction was at room temperature with gentle movement 
for 8–24 hours.  
 
Statistical Analysis. 
Values in the text and figures are presented as means ± standard deviations of 
experiments carried out in triplicate, at least. Each experiment was carried three 
times. Equal variance or separate variance two-sample student’s t-test were used, as 
appropriate, to compare two groups. Where appropriate, Bonferroni analysis was used 
to correct for multiple comparisons within a single experiment. 
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RESULTS:  
APP is a microRNA target gene with putative miRNA target sites in its 3’UTR: 
To identify putative microRNA target sites in APP 3’UTR we used the available 
bioinformatics algorithms online (miRBase and TargetScan). Using the initial screen 
using these two bioinformatics tools we identified putative microRNAs predicted to 
target APP 3’UTR (Table 3-1). Further by a microRNA literature search we then 
went on to identify the microRNAs targeting APP that are expressed in normal 
human brain (Table 3-2). To validate the whether the microRNAs are actually 
expressed in a normal  human brain, we obtained total brain RNA obtained from a 
Caucasian male, age 81 yrs and quantified miRNA levels using a semi-quantitative 
real time PCR (Figure 3-1). We observed a significant expression of all the brain 
expressed microRNA from table 3-2, in normal human brain.  
 
Brain expressed miRNA bind to their predicted target sequences and regulate 
gene expression: We transfected our APP 3’UTR luciferase reporter vector along 
with synthetic microRNA precursors in our Naïve-HEK 293 cell line. We observed 
that all the brain expressed microRNA, miR-324-5p, miR-106b, miR-153, miR-17-
5p, miR-106a and miR-495 significantly decreased luciferase expression. We have 
previously shown (Patel, Hoang et al. 2008) that brain expressed miR-106a can 
regulate human APP levels. It is therefore used as a positive control for all our 
experiments.  miR-132, a miRNA with high brain expression, with no target site in 
APP 3’UTR did not alter luciferase expression (Figure 3-2A). In contrast all the 
microRNAs co-transfected with the luciferase reporter bearing the APP 3’UTR with 
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the respective seed mutants for each miRNA, showed no effects on luciferase 
expression (Figure 3-2B). 
 
Brain expressed microRNA regulate endogenous APP levels in human cells lines: 
Having shown that the brain expressed microRNA bind to their putative target sites in 
APP 3’UTR and regulate reporter gene expression, we went on to further investigate 
whether these microRNAs also affect endogenous APP levels in our cell lines. 
Transient over expression of miR-324-5p, miR-106b, miR-153, miR-17-5p, miR-
106a and miR-495 in Naïve HEK-293 cells lead to a significant (~50%, p< 0.001) 
decrease in APP levels in these cells (Figure 3-3). We have previously shown(Patel, 
Hoang et al. 2008) that brain expressed miR-106a can regulate human APP levels. It 
is there used here as a positive control for all our experiments and miR-132 another 
brain expressed microRNA not targeting APP is a negative control for our 
experiments.  
 
All Brain expressed miRNA, except one, have no effect on APP mRNA levels: 
We further investigated whether the microRNAs were having a transcriptional or 
translational regulatory effect on APP levels. To do so we over expressed our pre-
miRNAs and measured APP mRNA levels by semiquantitative real time PCR. We 
observed no change in APP mRNA levels for miR-324-5p, miR-106b, miR-153 and 
miR-17-5p. However we saw a significant decrease (~50%, p <0.001) in APP mRNA 
levels for miR-495 (Figure 3-4). This therefore suggests that all miRNAs, except 
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miR-495 are having a translational regulatory effect of APP, whereas miR-495 may 
be having a transcriptional effect of APP mRNA levels.  
 
Endogenous microRNA expression in human neural progenitor cells: Human 
neural progenitor cells have the potential to develop into new neurons in vitro, and 
therefore can be potentially used for the repair or replacing damaged neurons in 
neurodegenerative diseases like Alzheimer’s disease(Lie, Song et al. 2004). Reports 
indicate that glial progenitor cells and their progeny from AD patients produce and 
release Aβ40 and Aβ42 and also generate drastically few neurons (He and Shen 2009). 
This might also hold true for adult neural progenitor cells in AD brains. We therefore 
measured the endogenous expression of brain expressed miRNA in human neural 
progenitor cells to determine if alterations in the endogenous miRNA levels might 
affect APP levels in these progenitors. Using semi quantitative real time PCR we 
observed significant endogenous expression of miR-324-5p, miR-106b, miR-17-5p 
and miR-106a in these undifferentiated human neural progenitor cells. We also saw a 
significant endogenous expression of miR-132, which is not predicted to target APP; 
in these cells. However we did not see any endogenous expression of miR-153 and 
miR-495 in these undifferentiated neural progenitors (Figure 3-5). miR-520c which is 
not a brain expressed miRNA showed no endogenous expression in these neural 
progenitors, which was expected.  
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Knockdown of endogenous microRNAs in human neural progenitors increases 
APP gene regulation: Using Anti-miR microRNA inhibitors we inhibited 
endogenous microRNA expression for miR-106a, miR-106b, miR-324-5p and miR-
17-5p in undifferentiated human neural progenitors cells. We transfected anti-miR 
inhibitors and these caused a significant increase in luciferase expression (~40% 
increase, p<0.001) (Figure 3-6A). Transfection of these inhibitors also led to a 
significant increase in APP protein levels in these cells (Figure 3-6B).  
 
miRNA mediated regulation of APP levels in primary neurons : We measured 
microRNA mediated regulation of APP expression in primary neurons cultured from 
brains of R1.40 APP transgenic mice. Over expression of hsa-miR-324-5p, miR-
106b, miR-153, miR-17-5p, miR-106a and miR-495 caused a significant decrease in 
APP levels in these primary neurons (Figure 3-7). This suggests that microRNAs 
could be involved in regulating APP levels in neurons in the brain and therefore 
might play an important role in AD pathogenesis.  
 
In situ hybridization: In situ hybridization in human brain tissue sections from a non 
demented and an AD individual revealed that miR-324-5p (Figure 3-8) and miR-17-
5p (Figure 3-8) are expressed strongly in human neurons. However no significant 
difference was observed for these microRNAs between the non-demented and AD 
brain tissue sections. As shown previously by (Nelson, Baldwin et al. 2006), miR-124  
used as a positive control (Figure 3-10) showed high expression in cortical neurons in 
the human cerebral cortex. In addition, miR-324-5p probe also labels some cells that 
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by morphology appear to by microglia (Figure 3-8c, 3-8d). It also stains the white 
matter, which includes glial cells with far fewer neurons. miR-17-5p probe also 
appears to stain the microglia (Figure 3-9c) but to a lesser degree when compared to 
the miR-324-5p staining for the same.  
     For In situ hybridization using probes for miR-106b, miR-153 the staining 
observed was no different than the background staining for our negative control miR-
520c and hence the results for miR-106b and miR-153 were inconclusive. We did not 
do in situ hybridization on miR-495 and miR-106a since these are not highly 
expressed in brain and it’s difficult to detect miRNA with low expression levels in the 
brain using this technique.  
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DISCUSSION:   
     APP is predicted has been predicted as a putative microRNA target gene and APP 
protein levels have been shown to be up regulated in hippocampal neurons in which 
AGO2 was silenced(Vilardo, Barbato et al.). This therefore suggests that APP is 
potentially regulated by microRNAs in hippocampal neurons.  
     We have previously shown APP regulation by miR-106a(Patel, Hoang et al. 
2008). Here we extend our studies to other brain expressed microRNA predicted to 
target APP mRNA and provide evidence that APP expression is regulated by brain 
expressed microRNA. In vitro experiments indicate that luciferase expression under 
the control of APP 3’UTR can be regulated by miR-106b, miR-17-5p, miR-324, miR-
153 and miR-495, all of which are brain expressed microRNA. Over expression of 
these microRNAs also reduce APP protein levels in our cell lines, further confirming 
the prediction that APP is a putative microRNA target gene. Importantly over 
expression of miR-106b, miR-17-5p, miR-324-5p and miR-153 did not change APP 
mRNA levels, which is typically observed for miRNA mediated gene regulation. 
However some studies have also shown decreased mRNA levels, of some microRNA 
target gene, as an effect of miRNA mediated gene regulation (Arora, Guduric-Fuchs 
et al. ; Yekta, Shih et al. 2004). Ribosome profiling studies have also shown that 
decrease in protein production correlate with change in the respective mRNA levels 
as an effect of miRNA on gene expression(Guo, Ingolia et al.). In accordance to these 
findings we also observed that miR-495, unlike the other brain expressed microRNA 
significantly decreased APP mRNA levels, suggesting that it might have a post 
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transcriptional effect on gene regulation, rather than a translational effect as observed 
for the other brain expressed microRNA.  
    We also extended our microRNA studies to human neural progenitor cells which 
have the potential to be differentiated into neurons. Recent findings have shown that 
certain areas of the brain generate new functional neurons throughout life from neural 
stem cells(Lie, Song et al. 2004) Hence this raises the possibility that neural stem 
cells can be used to replace dying neurons in AD. Indeed studies in AD transgenic 
animals have shown that neural precursor cells improve memory dysfunction in rats 
caused by injections of Aβ40 in the dorsal hippocampus, even though the underlying 
mechanisms remain unknown (Li, Gao et al.). Study has shown miR-20 mediated 
regulation of APP in glutamatergic neurons derived from embryonic stem 
cells(Hebert, Horre et al. 2008). In agreement with these findings we investigated 
whether our brain expressed microRNA regulate APP expression in neural progenitor 
cells. Our data indicates endogenous expression of miR-106a, miR-106b, miR-17-5p 
and miR-324-5p in undifferentiated neural progenitors. Knockdown of these 
endogenous microRNA significantly increased APP 3’UTR mediated luciferase 
expression in these undifferentiated neural progenitor cells. Knockdown of miR-106a 
also significantly increased APP protein levels in these cells. Our data therefore 
strongly suggest that miR-106a, miR-106b, miR-324-5p and miR-17-5p may 
contribute to regulation of APP expression in brain. Studies have shown decreased 
miR-29a/b1 and miR-107 expression in neurons in brain with increased BACE 1 
expression in AD (Hebert, Horre et al. 2008; Wang, Rajeev et al. 2008). Hence these 
neural progenitor cells with functional microRNA regulatory pathways could provide 
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attractive therapeutic targets for AD to replace non-functional microRNA regulation 
and restore miRNA mediated regulation of APP levels in the brain. However the 
differential expression of microRNA and its effect of APP regulation between 
undifferentiated and differentiated neural progenitor cells is an interesting possibility 
that needs to be addressed in further work.  
      APP is also highly expressed in the brain with APP695 isoform being predominant 
in the neurons (Arai, Lee et al. 1991). APP mis-regulation leading to increased APP 
levels and Aβ load in the brain have been implicated in the disease process 
(Theuns and Van Broeckhoven 2000; Rovelet-Lecrux, Hannequin et al. 2006). 
Hippocampus is one of the main brain regions affected in AD and it has been shown 
that miR-101 regulates APP expression in primary cultures of rat hippocampal 
neurons(Vilardo, Barbato et al.). It has also been shown that miR-20a family 
microRNAs regulate APP levels in primary cortical neurons from C57/BL6 mice 
during brain development in these mice(Hebert, Horre et al. 2008).Hence we 
analyzed APP expression, in primary neuronal cultures from R1.40 APP transgenic 
mice, in response to over expression of our brain expressed microRNA.  Our data 
suggests that over expression of miR-106a, miR-106b, miR-324-5p, miR-17-5p, miR-
495 and miR-153 decrease APP levels in these primary neurons and may possibly 
contribute to regulation of APP in the neurons in the brain. 
      microRNAs play an important role in gene regulation in healthy and diseased 
conditions. There it is necessary to characterize miRNA expression in different cell 
types under different conditions. In situ hybridization can demonstrate cell type 
specific expression of microRNA that would be lost in tissue level expression 
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profiling. Previous studies have performed in situ hybridization on human brain tissue 
sections in order to characterize distribution of some neuronally expressed 
microRNAs such as miR-107, miR-124, miR-125b and miR-320(Nelson, Dimayuga 
et al. ; Nelson, Baldwin et al. 2006; Wang, Rajeev et al. 2008). Interestingly in situ 
hybridization also demonstrated that miR-107 which regulates BACE1 expression in 
AD, is not only strong expressed in neurons in the cerebral cortex in a non-demented 
brain, but its expression declines in the cortical layers with abundant AD 
pathology(Wang, Rajeev et al. 2008). 
     Therefore we characterized brain cell type specific expression of our miRNAs of 
interest using this technique. We used probes for miR-324-5p, miR-17-5p, miR-106b, 
miR-153 to detect cell type specific expression of these microRNAs in the brains of a 
non demented individual and an Alzheimer’s disease brain. In situ hybridization using 
these probes demonstrated that miR-324-5p and miR-17-5p are highly expressed in 
neurons in the hippocampus and miR-324-5p also showed microglial staining in the 
grey and white matter whereas miR-17-5p also showed microglial staining in the grey 
matter but to a much lesser extent when compared to miR-324-5p. However we did 
not see any significant difference in the expression pattern of these microRNAs 
between the control and AD brain tissue. A previous study(Hebert, Horre et al. 2008) 
using qRT-PCR has shown that miR-106b is expressed more abundantly in human 
brains than miR-17-5p. However miR-106b probe for in situ hybridization revealed 
no cell type specific staining in the human brain tissue sections. Similar result was 
observed for miR-153. Both these miRNAs exhibited a staining pattern which was 
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comparable to our negative control therefore leading to inconclusive results for their 
cell type specific expression in the brain.  
       There are also some limitations to the current study. In situ hybridization is a 
relatively low throughput technique and has been demonstrated to be effective for 
only those miRNAs that are highly expressed in any particular cell type in a given 
tissue. Thus we only were able to evaluate the results for some miRNAs of our 
interest. miR-106a and miR-495 have been shown to have very low expression in the 
brain(Liang, Ridzon et al. 2007), therefore making it challenging to identify cell type 
specific expression patterns for these miRNAs using this technique. Also the brain 
sections from only two individuals (non demented control and AD) were used for the 
in situ study. It is therefore possible that study of a larger population would result in 
completely different results and greater variability.  
      Therefore our current study suggests that APP mRNA in the brain is the target of 
multiple brain expressed microRNAs as evident from our data. However the 
involvement of other brain, expressed microRNA, predicted by bioinformatics to 
target APP, cannot be ignored.  Therefore in conclusion our work suggests strong 
involvement of microRNAs in regulating APP expression in the brain and also 
demonstrates novel microRNA expression patterns for miR-324-5p and miR-17-5p in 
the human hippocampus. This now raises the possibility for further work to define the 
exact molecular mechanism of action of these brain expressed microRNAs in 
regulating APP expression.  
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FIGURE LEGENDS:  
 
Figure 3-1: Semi quantitative real time PCR showing significant expression of brain 
expressed microRNA in normal human brain, when compared to miR-520c which is 
not brain expressed microRNA.  
 
Figure 3-2: Brain expressed microRNA miR-324-5p, miR-106b, miR-153, miR-17-
5p, miR-106a, miR-495 bind to their predicted target sites in APP 3’UTR and 
negatively regulate gene expression. (A) Over expression of these microRNA 
significantly decreases luciferase expression (~50% decrease, p<0.001). (B) Over 
expression of these microRNA along with the APP 3’UTR bearing seed region 
mutants in the respective microRNA target sites does to show any effect on luciferase 
expression.  
 
Figure 3-3: Over expression of brain expressed microRNA significantly reduce APP 
protein levels in Naïve HEK-293 cell lines ( ~50% decrease, p<0.001) 
 
Figure 3-4: Over expression of brain expressed miR-324-5p, miR-106b, miR-153, 
miR-17-5p, and miR-106a have no effect on APP mRNA levels in Naïve HEK-293 
cell lines. Over expression of miR-495 significantly decreases APP mRNA levels 
(~50% decrease, p<0.001) 
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Figure 3-5: Semi quantitative real time PCR showing significant endogenous 
expression of brain expressed miR-324-5p, miR-106b, miR-17-5p and miR-106a in 
undifferentiated human neural progenitor cells. miR-495 and miR-153 are not 
endogenously expressed in these undifferentiated human neural progenitor cells. 
 
Figure 3-6: Knockdown of miR-106a, miR-106b, miR-324-5p and miR-17-5p in 
human neural progenitor cells. (A). Endogenous inhibition of microRNAs 
significantly increases reporter gene expression (40%, p<0.001).(B) Endogenous 
inhibition of these microRNAs also significantly increases APP protein levels in 
human neural progenitor cells.  
 
Figure 3-7: Over expression of miR-324-5p, miR-106b, miR-153, miR-17-5p, miR-
106a and miR-495 in primary neurons from R1.40 APP transgenic mice significantly 
reduce APP protein levels.  
 
Figure 3-8: In situ hybridization of miR-324-5p. (A), (B), (C) and (D). ISH 
performed on a non demented human brain tissue sections show that miR-324-5p is 
expressed in neurons and glial cells of the dentate gyrus as indicated by the red and 
black arrows respectively. (D) Microglial expression is also seen in the white matter 
 
Figure 3-9: In situ hybridization of miR-17-5p. (A), (B) and (C). ISH performed on a 
non demented human brain tissue sections show that miR-17-5p is expressed in 
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neurons and few glial cells of the dentate gyrus as indicated by the red and black 
arrows respectively.  
 
Figure 3-10: ISH performed on non demented human brain section shows that miR-
124 is enriched in (A) neurons of the cerebral cortex and also in (B) neurons in the 
dentate gyrus of the human hippocampus.  
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FIGURES; 
 
Figure 3-1: microRNA expression in Normal Human Brain 
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Figure 3-2A: Over-expressing brain expressed miRNA in Naïve 293 cells decreases 
reporter gene expression 
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Figure 3-2B: Over-expressing miRNA with their putative seed region mutant targets 
in APP 3’UTR have no effect on reporter gene expression. 
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Figure 3-3: Brain expressed microRNA regulate endogenous APP levels in human 
cells lines 
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Figure 3-4: Effect of Brain expressed microRNA on APP mRNA levels in human 
cells lines.  
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Figure 3-5: Endogenous microRNA expression in undifferentiated human Neural 
Progenitor cells.  
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Figure 3-6A: Knockdown of endogenous micoRNA in human neural progenitors 
increases APP 3’UTR mediated luciferase expression.  
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Figure 3-6B: Knockdown of endogenous micoRNA in human neural progenitors 
increases APP protein levels.  
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Figure 3-7: Over expression of brain expressed miRNA in primary neurons decreases 
APP protein levels.  
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Figure 3-8: In situ hybridization for miR-324-5p shows neurons and microglial 
specific expression in the hippocampus and in the white matter in the tissue section 
from a non demented individual.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 110
 
Figure 3-9: In situ hybridization for miR-17-5p shows neurons and microglial 
specific expression in the hippocampus in the tissue section from a non demented 
individual.  
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Figure 3-10: In situ hybridization for miR-124 in the tissue section from a non 
demented individual shows that miR-124 is enriched in cortical and hippocampal 
neurons.  
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TABLES:  
 
 
Table 3-1: Common list of miRNA predicted to target APP by both mirBase and 
TargetScan 
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Table 3-2 (Yu Liang 2007) Brain expressed miRNA predicted to target APP 
mRNA 
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ABSTRACT: 
Regulation of APP expression levels have been implicated in Alzheimer’s 
disease and have been suggested to play an important role in AD. It has been 
previously reported that APP levels can also be regulated post-transcriptionally by 
miRNAs by complementary binding between the miRNA and their target sequences 
in the 3’UTR of APP. However it has also been shown that such genetic regulation by 
the miRNA can be disrupted by the presence of genetic variants in the 3’UTR of 
miRNA target genes. Therefore it is possible that rare or unidentified genetic 
variations in the 3’UTR of APP may also play an important role in AD risk or 
pathogenesis. Here we identified a rare genetic variant, rs45455403 in APP 3’UTR, 
which is located in the putative miR-495 miRNA target site This lead us to 
hypothesize that this variant disrupts miR- 495 mediated repression of APP 
expression. In vitro follow-up of this finding suggests that hsa-mir-495 is expressed 
in brain and can regulate the expression of APP. Furthermore, reporter gene assays 
suggest that the mutated allele can increase the expression of APP as compared to the 
wild-type allele. For the first time, our data suggest that genetic variants within a 
potentially functional miRNA target site in the 3' UTR of APP can modify 
predisposition for AD. 
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INTRODUCTION: 
      Alzheimer’s disease (AD) is characterized by the accumulation of amyloid beta 
(Aβ) plaques, generated by the sequential cleavage of APP by the β-site APP cleaving 
enzyme 1 (BACE1) and γ-secretase (Dominguez, Hartmann et al. 2004). It has been 
shown that regulating the expression levels of the proteins involved in Aβ generation 
plays an important role in AD. A number of studies have A number of studies have 
shown that APP over-expression, resulting from either a genomic locus duplication or 
alteration in the APP regulatory sequences, can lead to development of early-onset 
Alzheimer’s disease (AD)(Brouwers, Sleegers et al. 2006; Sleegers, Brouwers et al. 
2006). This suggests that increased APP levels can increase AD risk. 
      A novel mechanism for regulating gene expression involves the action of 
microRNA, which are a major class of non coding RNAs involved in post 
transcriptional regulation of gene expression. MicroRNAs have been shown to 
regulate gene expression, specifically through complementary binding to their target 
sequence in the 3’UTR of target genes(Kim 2005). 
      Bioinformatics analysis predicts that APP 3’UTR contains unique miRNA target 
sites (MirBase; TargetScan). We have previously shown that APP levels can be 
regulated by miR-106a and miR-520c (Patel, Hoang et al. 2008). Other studies have 
also shown microRNAs belonging to the miR-20 family are involved in APP 
regulation during brain development and in differentiating neurons(Hebert, Horre et 
al. 2008). However it has also been shown that such genetic regulation by the miRNA 
can be disrupted by the presence of genetic variants in the 3’UTR of miRNA target 
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genes. Many 3’UTR target gene polymorphisms have been reported to be associated 
with differential gene expression of the miRNA targeted gene (Abelson, Kwan et al. 
2005; Mishra, Humeniuk et al. 2007). Therefore it is also possible that mutations or 
polymorphisms in the 3’UTR of APP can play an important role in AD pathogenesis. 
In addition it is possible that disruption of miRNA mediated expression regulation of 
other genes leads to increased AD risk. A recent study(Bettens, Brouwers et al. 2009) 
identified 29 variants in BACE1 3’UTR but no patient specific variants were detected 
in miRNA target sites that were reported to be regulating BACE1(Hebert, Horre et al. 
2008; Wang, Rajeev et al. 2008).One study (Bettens, Brouwers et al. 2009) also 
detected four patient specific variants in APP 3’UTR but none of those were located 
in previously reported miRNA target sites shown to be involved in regulating APP 
expression(Patel, Hoang et al. 2008). Therefore it is possible that other rare or 
unidentified genetic variations in the 3’UTR of APP may play an important role in 
AD risk or pathogenesis. This led us to investigate if polymorphisms in APP 3’UTR 
will disrupt miRNA binding and result in dysregulation of miRNA mediated gene 
regulation. 
         To test this idea, we identified a genetic variant within the APP 3’UTR of 
probands from early onset familial Alzheimer’s disease families linked to the APP-
region on chromosome 21. This variant, rs45455403, is located in the putative miR-
495 miRNA target site in the APP 3’UTR. Interestingly rs45455403 is also a rare 
SNP in the caucasian population, <1% of the population. However, this SNP is 
present in 6% of the African American population, suggesting that rs45455403 could 
be a risk factor for AD in this population. This therefore led us to hypothesize that 
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this variant disrupts miR- 495 mediated repression of APP expression. Here we 
demonstrate that SNP rs45455403 (588C to A) in APP 3’UTR affects APP expression 
by interfering with miR-495 function. Our data allows us to suggest genetic variants 
in APP 3’UTR can alter miRNA mediated regulation of APP gene thereby increasing 
APP levels and increasing AD risk. 
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MATERIALS AND METHODS: 
DNA sequencing of APP 3’UTR:  
We performed sequence analysis of the complete APP 3’ UTR region in the 
chromosome 21-linked families. We extended this 3’ UTR sequencing effort to least 
one proband in each family that comprise the entire NIMH sample (n=449). Age of 
onset for all AD cases was determined by a clinician based on an interview with a 
knowledgeable informant and review of any available records. 
 
Reporter Vectors and DNA constructs:  
 The 3’UTR of APP (~1.2kb) was amplified from pGALA- luciferase vector with 
both APP 3’UTR and APP 5’UTR sequences (Rogers, Randall et al. 2002) and 
cloned into pMIR-REPORT luciferase vector (Ambion). Insertion of the UTR was 
confirmed by sequencing.  The APP 3’UTR luciferase vector was mutagenized using 
the QuickChange Site Directed Mutagenesis kit (Stratagene) according to the 
manufacturer’s instructions. Specifically, the seed region of the putative miR-495 
target site (underlined) :                                                                                                            
5’ AAGAGGATACACACGTTTGTTT 3’was mutated to                                                
5’ AAGAGGATACACACGTGGCCTT 3’. To introduce the minor allele of 
rs454455403 (bolded) the miR-495 target site was mutated to                                           
5’AAGAGGATACACAAGTTTGTTT 3’ and 
5’AAGAGGATACACATGTTTGTTT 3’.  
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Cells and Cell Culture: 
Naïve human embryonic kidney (HEK)-293 cells were purchased from ATCC. Cells 
were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml Penicillin and 100 μg/ml 
streptomycin. 
 
Transfections and Luciferase Assays: 
10,000 Naïve HEK-293 were plated in 24 well plates. The next day, cells were 
transfected with a miRNA over expression vector. Reporter vectors bearing either the 
miRNA target sequence or the miRNA seed region mutant target sequence or the 
reporter vectors bearing the miR-495 target site SNP in the APP 3’UTR, and one 
tenth of the molar volume of pRL-SV40, a Renilla Luciferase control vector. We 
utilized Arrest-In transfection reagent (Open Biosystems Inc.); any differences in 
transfection efficiency were accounted for by measuring Renilla luciferase activity. 
48 hours posttransfection, cells were lysed using 100 μL of GLB (Glo Lysis Buffer, 
Promega). Firefly and Renilla luciferase activities were measured using a dual 
luciferase reporter assay kit (Promega), per the manufacturer's protocol. Firefly 
luciferase activity was normalized to Renilla luciferase activity. 
 
MicroRNA inhibition:  
Naïve HEK-293 (7500 cells) were plated in 96 well plates. The next day, cells were 
transfected with a 0.5 μg miRNA over expression vector, 0.05 μg reporter vectors 
bearing the miRNA target sequence, 50nM final concentration of Anti-miR-495 
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miRNA Inhibitor (Cat#AM11526, Ambion) or FAM™-labeled Anti-miR™ Negative 
Control (Cat#AM17012, Ambion), and one tenth of the molar volume of pRL-SV40, 
a Renilla Luciferase control vector. We utilized Lipofectamine 2000 reagent 
(Invitrogen); any differences in transfection efficiency were accounted for by 
measuring Renilla luciferase activity. 24 hours post-transfection, cells were lysed 
using 100 μL of GLB (Glo Lysis Buffer, Promega). Firefly and Renilla luciferase 
activities were measured using a dual luciferase reporter assay kit (Promega), per the 
manufacturer's protocol. Firefly luciferase activity was normalized to Renilla 
luciferase activity. 
 
Western Blot Analysis :  
Naïve HEK-293 cells were plated in 6 well plates, 200,000 cells per well. The next 
day, cells were transfected with a miRNA over expression vector. Cells were lysed in 
RIPA cell lysis buffer (50 mM Tris-HCL pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% 
NP-40, 1 mM PMSF and 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 1 μg/ml 
pepstatin), and centrifuged at 14,000 rpm for 15 minutes at 4°C. The resulting 
supernatant was transferred to a new micro-centrifuge tube. The protein concentration 
of the cell lysates was determined using the BCA protein assay kit (Pierce, Rockford, 
IL) according to the manufacturer's instructions. Equal quantities of protein were 
loaded into the wells of 4–12% Bis-Tris polyacrylamide gels (Invitrogen) along with 
Odyssey Protein Molecular Weight Markers (Licor Biosciences). Gels were run using 
MES running buffer and transferred to PVDF membrane (Immobilon PSQ, Millipore) 
using a semi-dry transfer apparatus (Owl Scientific) and NuPage transfer buffer 
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(Invitrogen). PVDF membranes were blocked in Odyssey Blocking Buffer (Licor 
Biosciences) for at least two hours, washed extensively in 1X PBS with 0.1% Tween, 
then incubated with primary antibody for either one hour at room temperature or 
overnight at 4°C. After removing the primary antibody, membranes were extensively 
washed and incubated with goat-anti-rabbit-IRDye or goat-anti-mouse-IRDye 
secondary antibodies (1:10,000; Licor Biosciences) for one hour at room temperature. 
Membranes were washed with 1X PBS without Tween and the blot was visualized 
using a Licor Odyssey Infrared imaging system (Licor Biosciences), and signals were 
quantified using the Odyssey software. To account for any differences in loading, 
target band densitometries were divided by actin densitometries obtained from the 
same lane. These corrected densitometries were normalized to controls in each 
experiment. 
 
Antibodies: 
A polyclonal antibody specific for the C-terminus of human APP (A8717; Sigma 
Aldrich, Inc) and a monoclonal antibody specific for human β-Actin (A5441; 
Sigma Aldrich) were used as primary antibodies. Secondary antibodies were IRDye 
goat anti-rabbit (Licor Biosciences) and IRDye- goat anti-mouse (Licor Biosciences). 
 
RNA extraction and Quantitative PCR: 
48 hours post-transfection, cells were washed with cold PBS and total RNA was 
isolated using RNeasy Mini Kit (Qiagen Inc.). To quantify APP mRNA levels, cDNA 
was synthesized using total RNA, N6 random primers and SuperScript II Reverse 
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Transcriptase (Invitrogen). cDNA was then diluted 1:15 using RNase free water and 
mixed with APP or GAPDH primer/probe sets (Applied Biosystems, Inc.; APP 
Catalog # Hs00169098_m1; GAPDH Catalog # Hs99999905_m1), 2× PCR Universal 
Master Mix (Applied Biosystems, Inc.) and amplified using an ABI 7500 Real Time 
PCR system following the manufacturer's directions. GAPDH was used as an internal 
control. To determine differences in APP mRNA levels, we utilized the ΔΔCt 
method. 
    To quantify miRNA levels from normal human brain, total brain RNA was 
obtained from Ambion. cDNA was then reverse transcribed from total RNA sample 
using specific miRNA primers from the TaqMan MicroRNA Assays and reagents 
from the Taq Man MicroRNA Reverse Transcription kit (Applied Biosystems). The 
resulting cDNA was amplified by PCR using TaqMan MicroRNA Assay primers 
with the TaqMan Universal PCR Master Mix and analyzed with a 7500 ABI PRISM 
Sequence Detector System (Applied Biosystems) according to the manufacturer's 
instructions. The relative levels of miRNA expression were calculated from the 
relevant signals by the ΔΔCt method by normalization to the signal of RNU44. 
 
Statistical Analysis. 
Values in the text and figures are presented as means ± standard deviations of 
experiments carried out in triplicate, at least. Each experiment was carried three 
times. Equal variance or separate variance two-sample student’s t-test were used, as 
appropriate, to compare two groups. Where appropriate, Bonferroni analysis was used 
to correct for multiple comparisons within a single experiment. 
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RESULTS:  
rs45455403 and miR-495 target site in APP 3’UTR: The sequencing results for 
APP 3’ UTR region in the chromosome 21-linked families revealed no mutations. We 
extended this 3’ UTR sequencing effort to least one proband in each family that 
comprise the entire NIMH sample (n=449). These efforts resulted in the identification 
of a rare SNP (rs454455403; minor allele frequency 0.021) in one African American 
family (FAM: 50368) comprising two affected individuals (90C00627- AAO=66 & 
age=71, 90C00782 - AAO=57 & age = 72) that are heterozygous for SNP 
rs45455403. Sequence context of rs45455403 revealed that the polymorphism lays 
one base pair from the predicted seed region of a putative hsa-miR-495 target site 
(Figure 4-1). 
 
Hsa-miR-495 is expressed in normal human brain: Relative quantification for mir-
495 was done from total brain RNA obtained from a Caucasian male, age 81 yrs. 
Relative quantification of mir-495 mRNA levels shows that mir-495 is significantly 
(p< 0.001) expressed in normal human brain when compared to miR-520c which has 
been reported to not be expressed in brain (Figure 4-2).  
 
miR-495 binds to its putative target site in APP 3’UTR and regulates gene 
expression: We cloned the entire APP 3’ UTR (containing the major allele “C” of 
rs45455403) into a position immediately 3’ of  firefly luciferase reporter gene. Co-
transfection of this reporter vector in naïve HEK 293 cells along with a miR-495 
over-expression vector lead to a significant decrease in luciferase activity (~50%; p < 
0.001; Figure 4-3A) compared to reporter constructs where, either the miR-495 seed 
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region was disrupted by mutation or reporter construct lacking APP 3’UTR, thus 
confirming miR-495 can bind to the APP 3’ UTR and regulate gene expression. 
Inhibiting the over-expressed miR-495 using a anti- miR-495 inhibitor caused a 
significant increase in luciferase expression compared to a non-silencing control 
inhibitor ( ~40% ; p<0.001; Figure 4-3B).   
 
miR-495 over expression decreases APP protein levels and APP mRNA levels: 
Over expression of miR-495 also significantly decreased APP protein levels (~50%; p 
< 0.01; Figure 4-4A) and APP mRNA levels (~40%; p < 0.001; Figure 4-4B) 
compared to cells transfected with an empty-vector. Over-expression of miR-106a 
was used a positive control since its has previously been shown to regulate 
endogenous APP levels without affecting APP mRNA levels (Patel, Hoang et al. 
2008). Over-expression of miR-125b had no significant effect on APP levels as 
expected since APP contains no predicted miR-125b target sites. These results 
therefore demonstrate that the APP 3’UTR contains a productive miR-495 target site 
and can control APP expression levels. 
   
rs45455403 alters miR-495 mediated regulation of APP expression: To determine 
if rs45455403 might alter miR-495 mediated APP expression control, we mutated the 
miR-495 target site within the APP 3’UTR to replace the rs45455403 major allele (C) 
with the minor allele (A) (Figure 4-1). In addition, we also replaced the rs45455403 
major allele with a (T) which should increase complementarity between the target site 
and miR-495. We co-transfected these luciferase vectors along with a miR-495 over-
expression vector in naïve HEK 293 cells and observed that the miR-495 target site 
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harboring the rs45455403 minor allele (A) disrupts miR-495 mediated reporter gene 
expression observed with the major allele (Figure 4-5). The miR-495 target site 
engineered to increased complementarity with a (T) substitution increases miR-495 
mediated repression. This allele specific regulation is intriguing given that the major 
and minor alleles confer no changes in the complementarity between the target site 
and miR-495.  
 
Over-expression of the miR-495 position 9 mutant suppresses miR-495 mediated 
mediated regulation of APP expression:  To gain further insight into the mechanism 
of this allele specific miR-495 regulation we mutated position 9 of the mature miR-
495. This position is analogous to the rs45455403 position in the APP 3’UTR in that 
it is one basepair away from the predicted seed region (Figure 4-6A).  Mutation of 
miR-495 resulted in decreased repression luciferase activity compared to wild-type 
miR-495 (Figure 4-6B). As expected, over-expression of mutated miR-495 also 
resulted in decreased repression of APP protein levels compared to wild-type miR-
495 (Figure 4-6C). These results demonstrate miR-495 position 9 confers 
complementarity independent specificity to regulation of the APP miR-495 target 
site.   
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DISCUSSION: 
      microRNAs are known to inhibit gene expression by binding to their target 
sequences in the 3’UTR of their target genes. Evidence (Beyreuther, Pollwein et al. 
1993; Theuns and Van Broeckhoven 2000; Bettens, Brouwers et al. 2009)  has linked 
increased APP  to Alzheimer’s disease. An alternative means of potentially increasing 
APP expression levels, and therefore modulating AD risk, could be by dysregulation 
of APP expression. miRNAs have been implicated in neurodegenerative diseases and 
miR-106a(Patel, Hoang et al. 2008) and miR-20a family miRNAs(Hebert, Horre et al. 
2008) have been shown to regulate APP expression. 3’UTR polymorphisms in 
miRNA binding sites are reported to be associated with diseases such as muscular 
hypertrophy (Clop, Marcq et al. 2006) and methotrexate resistance in cancer (Mishra, 
Humeniuk et al. 2007). But no previous studies have looked at genetic variants in 
3’UTR of AD related genes. Therefore in this study we examined genetic variants in 
APP 3’UTR affecting microRNA binding to its putative target sequence in the 
3’UTR. 
         A study (Bettens, Brouwers et al. 2009) identified four genetic variants in the 
3’UTR of APP, but none of these were located in the miRNA target sites that were 
previously shown to regulate APP expression. To identify other, previously unknown 
variants in APP 3’UTR we screened for genetic variants in the APP 3’UTR in NIMH 
sample probands. Our Screening revealed one African American family with two 
affected individuals heterozygous for a minor allele in a rare SNP (rs45455403). This 
SNP is located 1 base pair outside of a predicted seed region of the putative miR-495 
target site in APP 3’UTR. In this report we present evidence that SNP 588C to A in 
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the miR-495 target sequence in APP 3’UTR affects APP expression by interfering 
with miR-495 function. This allele specific regulation suggests a novel pathogenic 
mechanism for AD whereby disruption of miRNA/APP mRNA interaction would 
lead to increased APP levels and eventually AD.  
         After finding evidence of miR-495 expression in human brain and that it can 
regulate APP expression, site-directed mutagenesis experiments demonstrated that the 
minor allele (A) of rs45455403 disrupts miR-495 mediated suppression of APP 
expression. This SNP is interesting since it is found exclusively in an African 
American population with a minor allele frequency of 0.067. For our NIMH sample 
(n=449) which included 58 African American individuals, only two affected 
individuals were heterozygous for the SNP resulting in a minor allele frequency of 
0.021, while the other remaining affected AD individuals were heterozygous for the 
wild type allele. The low allele frequency in our sample argues against a role of this 
variant in AD. However in spite of the limitations for the number of African 
American individuals in our sample size, we cannot exclude that any control 
individuals who might carry this variant may develop AD at a later stage. Also since 
in any given African American population, patients with AD might be negative and or 
positive for the SNP, non-AD patients might be positive for the SNP and some 
homozygotes for the genetic variant may or may not develop the disease, it is worth 
arguing that this SNP rs45455403 may not be determinant of the disease, but can be 
putative risk factor, resulting in increased vulnerability to Alzheimer's in individuals 
with that genetic variation (Jiang, Lee et al. 2008). Therefore for the identification 
and more stronger association of this variant with AD it will be vital to follow up with 
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a larger cohort of African American individuals which will provide a clearer picture 
of the extent to which this genetic variant in APP 3’UTR is relevant in Alzheimer’s 
Disease.  
        The miRNAs use the RISC (RNA induced silencing complex) to form an 
imperfect hybrid with the target mRNA, resulting in translational repression of the 
gene.(Bartel 2004). RISC comprises of the Argonaute (AGO) and PIWI (P-element 
induced wimpy testies) proteins. The Ago proteins have a N- terminal PAZ RNA 
binding domain and a C-terminal PIWI domain. Crystal structure of Agonuate protein 
shows that PAZ interacts with the target mRNA and serves as an anchor for the 3’end 
of the miRNA. The PIWI domain of the AGO protein also interacts with the miRNA 
and also forms contacts with the target mRNA (Parker, Roe et al. 2005; Song and 
Joshua-Tor 2006). A mutation in the mRNA binding pocket of PIWI domain of AGO 
prevents miRNA mediated messenger RNA target recognition (Ma, Yuan et al. 2005). 
Therefore the reverse, a mutation in the target mRNA interacting with the PIWI 
domain preventing target recognition by miRNA, can also hold true. Therefore it can 
be hypothesized that the SNP 588C to A in APP 3’UTR, may affect the binding of the 
PIWI domain of AGO protein to the 3”UTR of APP and preventing target recognition 
by miR-495. This mechanism might therefore be responsible for affecting APP 
expression by interfering with miR-495 function, resulting in APP over expression.  
       Thus this report is the first to show evidence for presence of a rare polymorphism 
in APP 3’ UTR – a key gene associated with AD – where the minor allele disrupts 
miR-495 binding to the 3’ UTR. Functional experiments reveal consequent 
substantial dysregulation of miRNA mediated suppression of APP expression levels. 
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The resulting increase in APP expression levels could result in higher predisposition 
to AD, due to increase in availability of APP substrate leading to higher levels of its 
neurotoxin metabolite Aβ42. 
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FIGURE LEGENDS: 
 
Figure 4-1: Putative mir-495 binding site in APP 3’UTR.A single nucleotide 
polymorphism is located within the putative target site for miR-495, specifically one 
nucleotide outside of the seed region 
 
Figure 4-2: Relative quantification of miR-495 mRNA levels show that miR-495 is 
significantly expressed in normal human brain (p<0.001). miR-520c has been 
reported as not being expressed in brain. Relative quantification for miR-495 was 
done from total brain RNA obtained from a Caucasian male, age 81 yrs 
 
Figure 4-3: miR-495 binds to its putative target site in APP 3’UTR and regulates 
gene expression. (A) Over-expressing hsa-mir-495 with its putative target sequence 
from APP 3’UTR resulted in a significant decrease in luciferase expression in Naïve 
293 cells (p=0.0001). This effect is reversed on over-expressing hsa-mir-495 with a 
mutant target sequence in which the binding site for the seed region of hsa-mir-495 
has been mutated. (B) Inhibition of the over-expressed mir-495 using siRNA  against 
mir-495 increased luciferase expression in Naïve 293 cells (p=0.0001) 
 
Figure 4-4: miR-495 over expression decreases APP protein levels and APP mRNA 
levels. (A) Over-expression of hsa-mir-495 and hsa-mir-106a significantly decreased 
APP protein levels when compared to the empty vector in Naïve 293 cells 
(p<0.0001).Over-expression of hsa-mir-125 had no effect on APP   protein levels. hsa-
mir-106a was used as a positive control and β-Actin was used as the loading control. 
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Quantification of the blot shows a 50% decrease in APP protein levels on over-
expressing hsa-mir-495 and hsa-mir-106a compared to the empty vector. No decrease 
was observed in APP   protein levels on over-expressing hsa-mir-125. (B) Quantitative 
RT-PCR detection analysis showed a decrease in the expression levels of APP mRNA 
on over-expression of hsa-mir-495 when compared to the empty vector. It has been 
previously shown that over-expression of hsa-mir-106a has no effect on APP mRNA 
levels. Therefore mir-106a is used here as a positive control. Hsa-mir-125b which is 
not predicted to target APP has been used as a negative control. 
 
Figure 4-5: rs45455403 alters miR-495 mediated regulation of APP expression. The 
miR-495 target site harboring the “A” minor allele disrupts miR-495 mediated 
reporter gene expression. A miR-495 target site engineered to increase 
complementarity with a “T” substitution increases miR-495 mediated repression. 
 
Figure 4-6: Over-expression of the miR-495 position 9 mutant suppresses miR-495 
mediated regulation of APP expression. (A) Position 9 mutant in miR-495 over 
expression vector. Mutation in this nucleotide in miR-495 is analogous to the SNP 
seen the target site for miR-495 in APP 3’UTR. (B) Over-expression of the position 9 
mutant of miR-495 results in increase luciferase activity compared to over-expression 
of wild-type miR-495. The effect was observed in luciferase reporter constructs 
harboring the wild-type “C” allele of rs45455403 and the synthetic “T” mutant at the 
same position. We did not expect to observe a difference in the reporter constructs 
harboring the “A” minor allele of rs45455403 nor the seed mutant since these result 
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in maximal luciferase activity. (C) Over-expression of miR-495 decreases APP 
proteins levels in Naïve 293 cells compared to miR-132 which does not target APP or 
the empty over-expression vector. Introduction of a mutation into the miR-495 
sequence at the position complementary to the nucleotide altered by rs45455403 leads 
to a significant increase APP levels compared to wild-type miR-495 over-expression.  
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FIGURES: 
Figure 4-1 miR-495 target site SNP is located one nucleotide outside of seed region. 
mir-495 binding to its putative target sequence. Highlighted nucleotide it the SNP 
with C=major allele and A=minor allele 
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Figure 4-2 miR-495 expression in normal human brain. 
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Figure 4-3A. Putative wild-type miR-495 target site can regulate gene expression 
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Figure 4-3B. Inhibition of miR-495 increases reporter gene expression.  
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Figure 4-4A. miR-495 decreases APP protein levels.  
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Figure 4-4B. miR-495 decreases APP mRNA levels. 
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Figure 4-5 rs45455403 in APP 3’UTR disrupts miR-495 mediated regulation of gene 
expression.  
 
 
 
 
 
Figure 4-6A. Position 9 mutation in the miR-495 over expression vector.  
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Figure 4-6B. Over-expression of the miR-495 position 9 mutant suppresses miR-495 
mediated luciferase expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 142
Figure 4-6C. Over-expression of the miR-495*“C” mutant suppresses miR-495 
mediated repression of endogenous APP levels in Naïve 293 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 143
CHAPTER 5 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
         Alzheimer’s disease is an irreversible neurodegenerative disorder, which is the 
major form of dementia in US. People usually develop this disease after 65 years of 
age. Amyloid deposition is one of the diagnostic brain lesions seen in Alzheimer’s 
disease patients and accumulation of amyloid beta plaques is associated with neuronal 
injury in the brain. Amyloid plaques constitute of  the β-amyloid protein, which is in 
turn derived from its large precursor protein APP (β-amyloid precursor protein), by 
sequential proteolytic cleavage by the β- and γ-secretase enzymes(Selkoe 2001). To 
date three main risk factors are known to increase the risk of AD. The most prominent 
risk factor is advancing age(Davies, Wolska et al. 1988), since the prevalence of AD 
is dramatically correlated to advancing age. Two other risk factors are rare familial 
mutations in the APP gene and in PS1 and PS2 genes which are components of the γ-
secretase enzyme complex (Citron, Oltersdorf et al. 1992; Tanzi and Bertram 2005). 
The third and most recently widely studied risk factor is APP expression. Head 
trauma is another factor which is believed to lead to AD, but is not necessarily 
identified as a risk factor (Roberts, Gentleman et al. 1991). Both advancing age and 
head trauma act at the level of APP expression and or APP turnover. Studies have 
shown that APP isoforms, APP770 and APP751 that include the Kunitz protease 
inhibitory (KPI) domain are selectively expressed with advancing age. A study shows 
that the APP751/APP695 mRNA ratio is increased in AD and it strongly correlated with 
the density of senile plaques in the hippocampus and entorhinal cortex. It was also 
shown that transfected cells expressing APP751 resulted in secretion of a lower 
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percentage of P3 and sAPPα and a higher percentage of Aβ42 and sAPPβ. This 
indicated that the KPI domain diminishes α-secretase cleavage of APP and therefore 
the amount of APP expressing the KPI domain may be an important factor 
influencing Aβ deposition in Alzheimer’s Disease (Johnson, McNeill et al. 1990; 
Rockenstein, McConlogue et al. 1995; Ho, Fukuchi et al. 1996). Head injury/trauma 
has been hypothesized to shear nerve terminal which in turn may interfere with APP 
metabolism due to an increase APP production and or alter APP turnover(Roberts, 
Gentleman et al. 1991). Head Trauma has also been show to increase Interleukin-I 
levels in the brain resulting in increased APP transcription and APP protein 
production thereby increasing the risk of developing AD (Goldgaber, Harris et al. 
1989; Griffin, Stanley et al. 1989). 
     Genetic conditions such as Down’s syndrome also result in increased APP 
expression due to trisomy 21 in individuals with DS. Such individuals invariably get 
AD if they live past 30 years of age (Beyreuther, Pollwein et al. 1993). Also in 
absence of trisomy 21, duplications of the APP gene locus results in increased APP 
expression and AD pathology in such individuals(Rovelet-Lecrux, Hannequin et al. 
2006; Sleegers, Brouwers et al. 2006). It has also been proposed that an imbalance 
between different transcription factors that regulate APP transcription, increases APP 
expression and AD risk(Beyreuther, Pollwein et al. 1993). APP promoter mutations 
have been identified in AD patients and that result in APP overproduction increasing 
their risk for developing AD (Brouwers, Sleegers et al. 2006). APP mRNA turnover 
has been shown to be regulated by a 29 nucleotide element in APP 3’UTR. Mutations 
in this nucleotide sequence have been reported to stabilize APP mRNA and increase 
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its half life resulting in more APP mRNA being transcribed and more APP being 
produced to undergo proteolytic processing(Rajagopalan and Malter 2000). While 
polymorphisms or mutations in this sequence have not been reported in AD patients, 
it could be possible that such mutations might lead to increased AD risk. Hence APP 
protein levels are central to the molecular etiology of AD, since the amount of Aβ 
produced will depend on the amount of APP being expressed and present in a cell to 
undergo amyloidogenic processing by secretases.Therefore it is crucial to understand 
the mechanisms by which APP expression is regulated.  
      Cellular proteins have always been involved in regulating cellular processes. But 
recently discovered non-coding RNAs are now known to play an important role in 
gene regulation. Most prominently, microRNAs (miRNAs) perform these regulatory 
functions. miRNAs are small ~22nt short RNA molecules that form imperfect base 
pairs with complementary target sequences in the 3’UTR of mRNAs and regulate 
gene expression (Flynt and Lai 2008). miRNAs have been shown to regulate 
numerous cellular processes, normal development and have also been shown to play 
an important role in regulation disease associated genes (Nelson, Wang et al. 2008; 
Stefani and Slack 2008). miRNAs are differentially expressed in different regions of 
the brain and have also been shown to be involved in neurodegenerative diseases such 
as Parkinson’s (Kim, Inoue et al. 2007) and more recent evidence has suggested the 
involvement of miRNAs in AD. 
     miRNA expression is altered in the brains of AD patients compared to age 
matched controls(Lukiw 2007). miR-29a/b and miR-107a have been shown to 
regulate BACE 1 expression (Hebert, Horre et al. 2008; Wang, Rajeev et al. 2008) and 
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miR-146a is associated in inflammatory signaling in AD(Lukiw, Zhao et al. 2008). 
Hence these findings strongly suggested that miRNAs play an important role in AD. 
Since APP is central to Alzheimer’s disease pathology, we therefore decided to focus 
on miRNA mediated regulation of APP expression. We identified 18 miRNAs 
targeting the APP 3’UTR, predicted by two most cited web based algorithms, 
miRBase and TargetScan(Grimson, Farh et al. 2007; Griffiths-Jones, Saini et al. 
2008). Since AD is a brain disorder affecting neurons, it is important to focus on 
miRNAs expressed in the brain and therefore of these 18 putative APP-targeting 
miRNAs, we identified six that are expressed in human brain. Having identified 
putative brain expressed miRNAs targeting APP, we were the first to demonstrate 
that APP levels can be regulated by miRNAs, specifically miR-106a and miR-520c 
(Patel, Hoang et al. 2008). Our findings were further confirmed by (Hebert, Horre et 
al. 2008), who demonstrated the miR-20a, miR-17-5p and miR-106b developmentally 
regulate APP in neurons. We also tested the effect of the remaining five brain 
expressed miRNAs and our results indicate that miR-106b, miR-17-5p, miR-495, 
miR-324-5p and miR-153 to their predicted target sites in the APP 3’UTR and 
negatively regulate reporter gene expression and as expected negatively regulate APP 
protein levels. For all of these miRNAs, except miR-495, over-expression does not 
alter APP mRNA levels suggesting that these miRNAs result in translational 
inhibition. In contrast, miR-495 does result in decreased APP mRNA levels. Utilizing 
a commercially available human neural progenitor cell line, we also determined that 
miR-106a, miR-106b, miR-324-5p and miR-17-5p are endogenously expressed in 
undifferentiated neural progenitors, while expression of miR-495 and miR-153 was 
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not detected. We inhibited these microRNAs and observed significant increases in 
APP 3’UTR controlled luciferase activity and also increased APP protein levels, as 
expected.  
Alzheimer’s disease is associated with neuron death resulting in synaptic loss 
and associated cognitive death. Hence is it importance to focus on miRNA mediated 
APP regulation in neurons. Also since miRNAs expression is cell type 
specific(Nelson, Wang et al. 2008), and we observe no endogenous expression of 
miR-495 and mir-153 in undifferentiated neural progenitors, it can by hypothesized 
that miRNAs are differentially expressed during neural differentiation. Hence 
differentiating these neural progenitors into neurons and determining the differential 
expression of our brain expressed miRNAs and the resultant changes in regulation of 
APP expression, is an interesting possibility that we plan to address in further work. 
       Since it is important to regulate APP levels in the brain to prevent neuronal death 
and cognitive decline associated with AD, we also analyzed APP expression, in 
response to miRNA over-expression, in primary neurons from APP transgenic mice. 
We utilized B6-R1.40, APP transgenic mice that harbor the entire genomic locus of 
human APP, including the complete 3’UTR (Lamb, Call et al. 1997; Ryman, Gao et 
al. 2008). This transgenic model expresses the Swedish mutant of APP and develops 
observable AD pathology in the cortex by 13 months of age. To our knowledge this 
was the only AD transgenic model that would allow us to test our hypothesis since all 
the other transgenic models don’t express human APP containing its 3’UTR. We 
observed a significant decrease in APP levels upon over expressing the brain 
expressed microRNAs in primary neuronal cultures from these transgenic mice, 
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which further validated our in vitro results from non-neuronal cells lines. Since these 
B6-R1.40 mice express the human Swedish APP high levels of Aβ are also detected 
in the brains of these mice (Lamb, Call et al. 1997). Having observed a significant 
microRNA mediated decrease in human APP levels in neurons from these mice, we 
hypothesize that the decrease in APP levels will also reduce Aβ production in these 
mice. Therefore these mice should also prove valuable to detect any associated 
changes in Aβ levels in response to the decreased APP levels. To further investigate 
this hypothesis we plan to over express brain expressed microRNAs which decrease 
APP levels, as previously observed by us, in primary neurons from these mice and 
test for Aβ changes by an Aβ Elisa assay.  
        Accumulation of Aβ, has also been shown to result in synaptic loss during early 
stages of Alzheimer’s Disease which correlates with memory dysfunction (Terry, 
Masliah et al. 1991). Dendritic spines are the major postsynaptic element and are 
important in learning, memory and cognition and a strong correlation has been 
observed between spine size, number and synaptic strength (Gray 1959; Zuo, Lin et 
al. 2005). Recent evidence suggests that dendritic spines are targets of Aβ oligomers. 
Although a number of miRNAs are found to be expressed in human brain, not much 
is known about miRNA and synapse regulation and their target genes. miR-134 was 
recently shown to negatively regulate dendritic spine development by inhibiting 
LimK1 that control spine development(Schratt, Tuebing et al. 2006). Based on these 
findings it would be interesting to study the effect of APP regulating miRNA on 
dendritic spine number, size and morphology in the B6-R.40 transgenic mice. To test 
this, in future, we plan to over express APP regulating microRNAs in primary 
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neurons from these transgenic mice and observe any changes dendritic spines when 
compared to primary neurons with no over expressed miRNA.  
     Previous studies have shown altered miRNA expression in advanced AD brains as 
well as changes stimulated by reactive metal elements in the brain (Lukiw 2007; 
Lukiw and Pogue 2007). Even though such miRNA expression analysis can provide 
important data, it is also necessary to understand the cellular level expression patterns 
for brain miRNA studies, since knowing which miRNA is expressed in which cell 
type can facilitate the identification of miRNA genes that are relevant to the disease. 
Using in situ hybridization, it was previously demonstrated that miR-107 which 
regulates BACE 1 expression is strongly expressed in human neurons in the brain 
cerebral cortex. However this expression is lost in brain sections with extensive AD 
pathology (Wang, Rajeev et al. 2008). Using the same technique we show that miR-
324-5p and miR-17-5p regulating APP expression is expressed in the neurons of the 
dentate gyrus in the hippocampus of human brain. miR-324-5p is also shows 
microglial expression in the hippocampus.miR-17-5p is also expressed in glia but to a 
much lesser extent when compared to the same observed for miR-324-5p. In addition 
miR-324-5p also stains the microglia in the white matter which is not observed for 
miR-17-5p. We did not observe any differences in staining between the non demented 
brain sections and the AD case. The staining observed for miR-106b and miR-153 
was no different than the background staining observed for our negative control 
therefore leading to inconclusive results for these two miRNAs.  
     There are also certain limitations to our current in situ study. Since this is a low 
throughput technique it is difficult to probe for miRNAs with low expression levels in 
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a given tissue. Thus we did not study the brain cell type specific expression profiles 
for miR-106a and miR-495 since they have been previously shown to have very low 
expression a normal human brain(Liang, Ridzon et al. 2007). Also our study is 
limited to the number of miRNAs that were evaluated. Identifying other miRNAs 
targeting APP 3’UTR, with high brain expression levels will be important to better 
understand the role of miRNAs in the progression on Alzheimer’s disease. Also the 
brain sections used in our current study were from only two individuals’ brains, one 
non-demented and one AD brain. Therefore it is highly possible that study of a larger 
population would result in a greater variability or even completely different results.  
       Thus our results so far have not only demonstrated an important role for miRNAs 
in regulating APP expression in cell lines and primary neurons, but have also 
demonstrated novel miRNA expression patterns in the human hippocampus. 
     However a possibility also exists that disruption of miRNA mediated regulation of 
APP expression might lead to increased APP levels and increased disease risk. 
Recently several groups have reported the role of miR-target site polymorphisms 
strongly associated with disease progression and drug response. For example 
polymorphism in the binding site for miR-189 in SLITRK1 gene has been strongly 
associated with Tourette’s syndrome (Abelson, Kwan et al. 2005). miR-206 binding 
site polymorphism in the ESR1 gene has been reported in breast cancer(Shao and 
Brown 2004). Also miR-433 target site polymorphism in FGF20 has been associated 
with Parkinson’s disease (Wang, van der Walt et al. 2008).  Polymorphisms in all of 
the above target genes have been reported to be located within miRNA binding sites. 
However one study (Mishra, Humeniuk et al. 2007) reported a polymorphism 15bp 
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away from the target site for miR-24 in DHFR gene to have an effect on gene 
expression thereby conferring drug resistance in cancer patients.  
     Genetic variability within APP 3’UTR has not yet been described. We therefore 
investigated whether polymorphisms in miRNA binding sites of APP 3’UTR for 
specific miRNAs might affect AD risk. A recent sequencing study of APP 3’UTR  by 
(Bettens, Brouwers et al. 2009) revealed six genetic variants four of which were 
present in AD patients. Of the four, two variants (171T>C and 454A>G) were located 
in putative target sites for miR-147 and miR-203 as predicted by PicTar and 
TargetScan. However there is no validated experimental evidence to underscore the 
potential relevance of these predicted sites in APP regulation. We, in collaboration 
with Dr. Tanzi’s laboratory (Genetics and Aging Research Unit, Massachusetts 
General Hospital), identified a genetic variant (588C>A) within the APP 3’UTR of 
probands from early onset familial Alzheimer’s disease families linked to the APP-
region on chromosome 21. This variant, rs45455403, is located in the putative miR-
495 miRNA target site in the APP 3’UTR. This led us to hypothesize that this variant 
disrupts miR- 495 mediated repression of APP expression. Our functional data 
demonstrates that the minor allele of rs45455403 disrupts miR-495 binding to its 
target sequence and results in allele specific regulation of APP expression. 
Interestingly rs45455403 is a rare SNP in the caucasian population, <1% of the 
population, but is present in 6% of the African American population, suggesting that 
rs45455403 could be a putative risk factor for AD in this population. Together with 
Dr. Tanzi’s laboratory (Genetics and Aging Research Unit, Massachusetts General 
Hospital), the entire NIMH AD genetics sample was screened for the rs45455403 
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polymorphism. Given that this sample is overwhelmingly caucasian, it was not 
surprising to find only two individuals that carry this polymorphism. Interestingly 
these two individuals were both African American and both have been diagnosed 
with AD. At this time we are obtaining additional DNA samples (and brain samples if 
possible) from AD and Non-AD African American Individuals for determining a 
genetic association of the SNP with the disease.  
       However discovering a valid association will not prove that rs45455403 is 
causatively involved in Alzheimer’s disease. rs45455403 will not be a determinant of 
the disease since some patients with AD might be negative for the polymorphism and 
some bearing the polymorphism might never develop the disease. Also since multiple 
processes play a role in regulation of APP levels and AD pathogenesis and since 
miRNAs are only one of the possible mediators, even if rs45455403 genetic variant in 
miR-495 target site does reveal a strong association with AD in our further studies, it 
does not necessarily imply that it is the actual and only risk variant for confirming the 
risk of acquiring AD.  
     We have also identified other single nucleotide polymorphisms in APP 3’UTR that 
are close to or within a miRNA target site. We have identified single nucleotide 
polymorphisms, from the NCBI SNP database, which are located near or within a 
miRNA target site for other putative miRNAs predicted to target APP. We found that 
SNP rs1059461 is located 25bp outside of the miR-376a/b microRNA target site and 
rs45541739 which is located within the miR-376a/b target site and rs1059478 which 
is located 7bp outside of the miR-29a/b and miR-29c target site in APP 3’UTR.  It 
has previously been reported that SNPs outside of a miRNA target site can affect 
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miRNA mediated gene regulation (Mishra, Humeniuk et al. 2007). Therefore it would 
be interesting to see if the polymorphisms located outside of the miR-376a/b and 
miR-29a/b/c target sites have an allele specific effect on miRNA mediated APP gene 
regulation. Interestingly SNP rs45541739 (minor allele A, major allele G) which is 
located in the miR-376a/b target site is also reported to be found only in African 
Americans with a minor allele frequency of 4.5%. As a part of our future studies we 
plan to investigate if the minor allele for this SNP has any effect on miR-376a/b 
mediated APP gene regulation, similar to what we observe for the miR-495 
polymorphism. Also this SNP in the miR-376a/b target site is located at nucleotide 17 
(of the target site) and the presence of the SNP disrupts miRNA binding to its target 
site at this nucleotide. Bioinformatics’ analysis has shown that Watson and Crick 
base-pairing to miRNA nucleotides 12 to 17 in absence of a perfect seed pairing was 
most associated with down regulation of the target gene(Grimson, Farh et al. 2007). 
Hence it is an interesting possibility to test whether this SNP at nucleotide 17 in the 
miR-376a/b target sites disrupts miRNA binding. This would not only be important in 
APP gene regulation but would also further validate the bioinfomatic predictions of 
miRNA and target site interactions.  
    Our studies therefore experimentally validate different brain expressed miRNA 
predicted to target APP and regulate its expression. However AD is a genetically 
complex disease and many genes have been associated with disease risk. While other 
studies have shown that miRNAs also regulate BACE (Hebert, Horre et al. 2008; 
Wang, Rajeev et al. 2008), there is no evidence so far for miRNA mediated gene 
regulation of other AD associated genes.  Therefore as a part of our future studies we 
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identified other putative genes associated with AD which are also regulated by our 
experimentally validated microRNA targeting APP. All the putative targets (~1000 
targets for each miRNA) predicted by miRBase for these six microRNAs miR-106a, 
miR-106b, miR-495, miR-17-5p, miR-324-5p and miR-153 were analyzed using 
DAVID analysis which is a bioinformatics tool for systemic and integrative analysis 
of large gene lists(Huang da, Sherman et al. 2009). The analysis resulted in 6 genes 
genetically associated with AD which other than APP, are also putative targets of our 
brain expressed microRNAs (Table 5-1). 
          We found that miR-106a, miR-106b and miR-17-5p all target the same genes 
SORL1 and SPTLC1. SORL1 also known as Sortilin Related Receptor L is known to 
interact with APP in the Golgi and Endosomes to reduce Aβ production and 
decreased SORL1 has been shown to result in increased Aβ production. SORL1 
expression has also been found to be reduced in neurons of AD patients (Scherzer, 
Offe et al. 2004; Andersen, Reiche et al. 2005). Genetic variants in SORL1 have been 
associated with AD(Meng, Lee et al. 2007; Rogaeva, Meng et al. 2007; Li, Rowland 
et al. 2008) and SORL1 is number six in the list of top 50 genes genetically associated 
with AD as listed by Alzgene (Bertram, McQueen et al. 2007).  
SPTLC1 encodes subunit C1 of serine palmitoyltransferase which is the rate 
limiting enzyme in spingolipid synthesis. Mutations in this gene results in increased 
ceramide levels that lead to axon and neuronal degeneration in mice and an analogous 
increase is seen in AD brains and HIV dementia patients. Cell culture studies also 
provide evidence of dysfunction and neuron death due to increased ceramide levels. 
(Cutler, Pedersen et al. 2002; Cutler, Haughey et al. 2004; Cutler, Kelly et al. 2004). 
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        David Analysis also identified DAPK1 and ACE also associated with AD, which 
were predicted to be putative targets of miR-324-5p. Both DAPK1 and ACE are 
among the top 50 genes listed to be genetically associated with AD by Alzgene 
(Bertram, McQueen et al. 2007). DAPK1 is a calcium calmodulin dependent serine 
threonine kinase that plays a role in neuronal apoptosis and is predominantly 
expressed in the brain and lungs (Yamamoto, Takahashi et al. 1999). Increased 
DAPK1 activity results in neuronal death and neurons with less DAPK1 expression 
are less likely to undergo apoptosis (Pelled, Raveh et al. 2002).  DAPK1 transcripts 
show allele specific expression and two SNPs identified within this gene are 
significantly associated with regulating DAPK1 allelic expression suggesting genetic 
association of DAPK1 with Alzheimer’s disease (Li, Grupe et al. 2006). ACE1 
encodes the angiotensin converting enzyme which is important in maintaining blood 
pressure. This enzyme was also found to significantly inhibit Aβ aggregation(Hu, 
Igarashi et al. 2001). An Alu repeat insertion variant in this gene is the most widely 
studied variant in AD. Individual with this genetic variant are 20% susceptible for 
increased risk of AD.  
      miR-495, besides targeting APP, is also a predicted to be a putative regulator of 
CH25H and IL1-β. Again both CH25H and IL-β are again among the top 50 genes to 
be genetically associated with Alzheimer’s disease as listed on Alzgene (Bertram, 
McQueen et al. 2007). CH25H encoding cholesterol 25-hydroxylase is a 
transcriptional regulator of genes involved in cholesterol and lipid metabolism. 25-
hydroxycholesterol can also lead to changes in Aβ levels by altering APP trafficking 
and processing in vitro(Zerbinatti, Cordy et al. 2008). This gene also maps to the AD 
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linkage region on chromosome 10 thus representing a functional and positional 
candidate gene for AD (Riemenschneider, Mahmoodzadeh et al. 2004; Bertram, 
McQueen et al. 2007). IL1-β is a pro-inflammatory cytokine, a main component of 
the inflammatory pathway and is over expressed in AD brains(Rogers, Leiter et al. 
1999). SNP in this gene increase the rate of mRNA synthesis or its stability 
(Dominici, Cattaneo et al. 2002). Polymorphisms in the IL-1β gene are associated 
with AD but many genetic studies on the association are still inconclusive (Grimaldi, 
Casadei et al. 2000; Green, Harris et al. 2002). 
       miR-153 does not target any other AD associated gene other than APP. Hence 
from this initial DAVID analysis it could be concluded and miR-106a, miR-106b, 
miR-495 and miR-324-5p might play an important yet complex role in AD 
pathogenesis. We therefore intend to study and experimentally validate our brain 
expressed microRNAs as regulators of these other AD associated genes. These 
studies have the potential for indentifying these microRNAs as novel regulators of 
these genes.  
     Taken together, our results demonstrate that APP levels can be regulated by 
miRNAs in vitro in cell lines and primary neurons and that genetic variants in APP 
3’UTR can alter miRNA mediated regulation of APP gene thereby increasing APP 
levels and increasing AD risk. So next we plan to determine if the effects observed by 
us in vitro are recapitulated in vivo. To answer this question for the validated 
miRNAs targeting APP in vitro, we will utilize a transgenic model of AD, B6-R1.40 
mice that harbor the entire genomic locus of human APP, including the complete 
3’UTR (Lamb, Call et al. 1997). These mice express the human Swedish APP 
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mutation and develop AD pathology by 13 months of age. To our knowledge this is 
the only AD transgenic model that will allow us to test our hypothesis since all the 
other Tg models don’t express human APP containing its 3’UTR. We will 
stereotactically inject bilaterally lentiviral particles that over-express and silence 
experimental and control miRNAs into the cortex of six-week-old male mice. Four 
weeks post-injection brain tissue will be harvested and utilized for quantitative 
Western blot and ELISA to measure APP and Aβ levels respectively. The brains of 
these animals will also be analyzed for changes in AD neuropathology using 
immunohistochemisty.  These in vivo experiments would not only be a significant 
validation of our in vitro results for our miRNA of interest but may also be useful in 
future work that would improve the ability to predict who will develop AD and could 
lead to the development miRNA-based drugs to treat AD. 
      So far there is no effective therapy for Alzheimer’s disease. AD being a brain 
disease makes it challenging to design or develop a drug that would cross the blood 
brain barrier effectively to delay the progression of the disease. However very 
recently a trial was conducted on MCI (Mild Cognitive Impairment) patients for a 
drug Posiphen® by QR Pharma Inc., which is currently under clinical development as 
an oral treatment for Alzheimer’s disease. They found that Posiphen and metabolites 
enter the brain readily and show a 2 to 2.5 time longer half-life in brain than in 
plasma, leading to prolonged efficacy and possible once a day dosing. They have 
shown that Posiphen lowers the levels of APP in plasma and CSF proving that its 
mechanism of action in humans is inhibition of APP synthesis. This is the first drug 
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which was shown to decrease APP levels in the brain unlike other AD drugs which 
are usually developed to target the amyloid beta aggregates.  
     Currently many studies have linked the deregulated expression of miRNAs to a 
variety of diseases; one of it being Alzheimer’s disease (Lukiw 2007; Hebert, Horre 
et al. 2008; Hebert, Horre et al. 2008; Wang, Rajeev et al. 2008). This implies that 
miRNAs can potentially be developed as a novel class of therapeutics targets. 
Specific knockdowns of target miRNAs using siRNA technology or over expression 
of miRNA duplexes using vectors encoding these miRNAs are promising methods to 
be translated into therapeutics agents in the future for treatment at the cellular level. 
Pioneering studies have shown that intraperitoneal injections of anti miR 
oligonucleotides (AMO), with special 5’ and 3’ modification, designed to inhibit 
miR-122 not only inhibited miR-122  but also significantly degraded it in the liver 
and other tissues except the CNS(Krutzfeldt, Rajewsky et al. 2005; Davis, Lollo et al. 
2006; Esau, Davis et al. 2006). These AMO were modified to protect against nuclease 
degradation and to improve pharmacokinetic properties such as increased half-life in 
serum. Since some miRNAs are down regulated in Alzheimer’s disease and certain 
cancers, restoring the levels of these miRNA by miRNA over expressing vectors 
could provide a therapeutic benefit by reinstating the regulation of target gene. 
However, in vivo application of this approach still awaits confirmation. Also since a 
single miRNA regulates hundreds (if not thousands) of genes, therapeutic 
applications that only interfere with the regulation of a particular miRNA on a 
particular target gene are required.  To address this possibility (Xiao, Yang et al. 
2007) designed antisense oligonucleotides (ODN) with locked 5’ and 3’ends entirely 
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complimentary to the miRNA target sequence in cardiac HCN2 and HCN4 genes. 
These ODNs bind to the target sequence preventing the miRNA from binding and 
thereby stopping the action for that microRNA on the HCN2 and HCN4 genes only. 
Thus this approach might be more appropriate for regulation of a target gene by a 
particular miRNA without affecting the regulatory effects of that miRNA on other 
target genes. Thus miRNAs could be an invaluable tool for biological research and 
more importantly for therapeutic intervention.  
     To summarize we experimentally validated the predicted effects of six brain 
expressed miRNAs bioinfomatically predicted to target APP 3’UTR and regulate 
APP gene expression. We have shown that miR-106a, miR-106b, miR-495, miR-17-
5p, miR-324-5p and miR-153 are expressed in normal human brain and bind to their 
predicted target sequences in APP 3’UTR and regulate APP gene expression by 
reducing APP protein in Naïve HEK 293 cells. None of these miRNAs, except miR-
495 have an effect on APP mRNA levels. miR-495 significantly decreases APP 
mRNA levels. We have further shown that these miRNAs also significantly reduce 
APP protein levels in primary neurons from B6-R1.40 APP transgenic mice. miR-
106a, miR-106b, miR-17-5p and miR-324-5p are also endogenously expressed in 
human neural progenitor cells and endogenous knockdown of these miRNA using 
Anti-miR-miRNA inhibitors significantly increases APP levels in these neural 
progenitors. We have also identified a genetic variant within the APP 3’UTR of 
probands from early onset familial Alzheimer’s disease families linked to the APP-
region on chromosome 21. This variant, rs45455403 is present in 6% of the African 
American population and is located in the putative miR-495 miRNA target site in the 
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APP 3’UTR. Our functional data demonstrates that the minor allele of rs45455403 
disrupts miR-495 binding to its target sequence. Since mutating the genomic copy of 
the APP 3’UTR is not possible, mutating position 9 of the miRNA complementary to 
the rs45545403 variant nucleotide within the APP 3’UTR significantly altered APP 
protein levels when compared to the wild type miR-495. These results suggested that 
the minor allele of rs45455403 results in allele-specific regulation of APP levels by 
miR- 495. Our study has therefore demonstrated that human APP levels can be 
regulated by miRNAs in vitro, and that rare genetic variants within the 3’UTR of 
APP may alter miRNA mediated regulation of APP expression, thereby increasing 
APP levels and possibly increasing AD risk. 
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TABLES:  
Table 5-1: Genes associated with Alzheimer’s disease targeted by brain expressed 
miRNAs 
 
miRNA AD associated target genes 
hsa-miR-324-5p DAPK1, ACD 
hsa-miR-106b SORL1, SPLTC1 
has-miR-153 ____ 
hsa-miR-17-5p SORL1, SPLTC1 
hsa-miR-106a SORL1, SPLTC1 
hsa-miR-495 Ch25H, IL1B 
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